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THESIS ABSTRACT
Type 2 diabetes mellitus is characterised by relative insulin deficiency. Furthermore, the pattern
of insulin secretion is abnormal, with reduced first and second phase insulin secretion,
increased irregularity of insulin release and diminished insulin pulses. Previously it has been
reported that P-cell rest (in the form of transient inhibition of insulin secretion) improves
insulin secretion in humans with Type 2 diabetes mellitus and animal models of diabetes. The
specific mechanism through which this was achieved remains unknown. In this MD thesis, I
undertook four related projects that address the pattern of insulin secretion and the specific
mechanism by which p-cell positively influences these.
Project one: Direct measurement of the pattern of insulin release in the portal vein
(immediately downstream of the pancreas) in human subjects in the basal state and in response
to glucose stimulation.
Project two: Examination of the effects of acute inhibition of insulin secretion in humans with
Type 2 diabetes by diazoxide on the pattern of insulin secretion.
Project three: Development and validation of a method to quantify pulsatile insulin release by
cultured human islets in an open loop perifusion system.
Project four. Use of the system developed and validated in project 3 to test the hypothesis that
transient P-cell rest in human islets induced by diazoxide (inhibiting insulin secretion by
opening P cell potassium channels) prevents loss of first phase insulin release and pulsatile
insulin secretion caused by culture of the islets in glucose concentrations comparable to those
seen in Type 2 diabetes.
In these experiments, the following observations were made; (1) when insulin secretion was
measured directly in the portal circulation in human subjects, hyperglycaemia enhanced insulin
secretion through the specific mechanism of amplification of the secretory burst mass while the
insulin pulse frequency remained unchanged; (2) acute partial inhibition of insulin secretion by
diazoxide in patients with Type 2 diabetes did not effect the regularity of insulin secretion but
did decrease the insulin clearance rate; (3) a deconvolution programme was established that
was able to detect 90% of insulin pulses delivered by single human islets and (4) using the
novel islet perfusion system it was possible to show that human islets cultured at high glucose
concentrations lost first phase insulin secretion and insulin pulse amplitude but these were
restored in islets exposed to a transient period of (3-cell rest.
The overall conclusion of these studies is that the dynamics of insulin secretion are important
as well as the absolute secretion rate and that the abnormalities in these dynamics may be
related in part to (3 cell insulin stores that can be manipulated by transient |3 cell rest.
Chapter 1
Pulsatile insulin secretion - a literature review
Introduction
The neuro-endocrine system secretes hormones in pulsatile manner (1,2). Pulsatile
hormone secretion has been shown to improve target organ sensitivity (3,4).
Disrupted function of the hypothalamo-pituitary axis is often characterised by
perturbation of the pulsatile pattern of secretion (5). The endocrine pancreas has
many properties in common with the hypothalamo-pituitary axis including pulsatile
release of hormones. Oscillations of the plasma insulin concentration were first
shown by Goodner et al who reported insulin oscillations with periodicity of 10
minutes in rhesus monkeys (6). A similar oscillatory pattern has been subsequently
demonstrated in vivo in humans (7), dogs (8) and baboons (9) and in vitro, in the
isolated canine pancreas (10), groups of perifused human islets (11), single rat (12)
and mouse (13) islets and single human P-cells (14). In the fasting state, the majority
of insulin (at least 70%) is released in the pulsatile mode (8,15) and the regulation of
insulin secretion occurs via modulation of this pulsatile component (16-19).
Moreover, abnormal patterns of pulsatile insulin secretion have been reported in
patients with type 2 diabetes mellitus (20) and their first-degree relatives with
normal (21) and abnormal (22) glucose tolerance implying that the disruption of the
oscillatory pattern of insulin secretion may play an important role in the
pathogenesis of this condition.
Physiology of insulin secretion
The p-cell secretes insulin in response to both neurohormonal (such as
acetylcholine) and nutrient stimuli (23,24). The signal transduction of these two
classes of agonist is distinct since the former interacts with a plasma membrane
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receptor whereas the latter is initiated by intracellular metabolism of the nutrients
(23,24). Various nutrients have the ability to stimulate insulin release. This includes
glucose, amino acids, free fatty acids (FFA) and ketone bodies (23). Of these,
glucose is the major physiological stimuli.
The pathway of glucose-induced insulin secretion has been extensively studied.
Since the identification of the ATP-sensitive potassium (Katp) channel in 1984 (25),
this channel was found to be involved in the mechanism of glucose-induced insulin
secretion (26-28). This pathway is referred to as the KAtp channel-dependent
pathway. The mechanism by which glucose stimulates insulin secretion in this
pathway is as follows (29-31) (figure 1); glucose is transported into the (3-cell via
glucose transporter, enters the glycolytic pathway and phosphroylated to glucose-6-
phosphate by glucokinase. This step consumes ATP and generates ADP resulting in
transient decrease in ATP/ADP ratio. This has the dual effect of stimulating
glycolysis via activation of phosphofructokinase (PFK) and mitochondrial
metabolism via activation of mitochondrial dehydrogenases and the respiratory
chain. This results in increased rates of glycolysis and oxidative phosphorylation
leading to the elevation of ATP/ADP ratio which in turn, closes the Katp channel
causing membrane depolarisation (32), influx of extracelullar Ca2+ via L-type
voltage-gated Ca2+ channels (33) and a rise in cytosolic Ca2+ concentration [Ca2+]j
(34). The elevation of [Ca2+]j activates Ca2+/calmodulin-dependent protein kinase II
(CaMK II) which phosphorylates proteins involved in the exocytosis of insulin






























Model of the regulation of insulin secretion from (3-cell by cytosolic ATP/ADP ratio and
K+-ATP channel closure. Abbreviations: GK - glucokinase; G6P - glucose-6-phosphate;
F6P - fructose-6-phosphate; PFK - phosphofuctokinase; PK - pyruvate kinase; CaMKl 1
Ca2+/calmodulin-dependent protein kinase 11; T* - membrane potential; [Ca2+]j -
cytoplasmic Ca2T concentration
However, it became apparent that the Katp channel-dependent pathway only
partially accounted for the mechanism of insulin secretion (36). Stimulation with
glucose produced far greater insulin response especially during the second phase
secretion than high concentration of KC1 or sulphonylurea, both of which caused
simple membrane depolarisation. Furthermore, an increase in [Ca2+]i did not
reproduce the biphasic response induced by glucose. These observations implied the
existence of additional mechanisms by which glucose could enhance insulin
secretion. In 1992, it was demonstrated that glucose strongly augmented insulin
secretion when the Katp channel was kept in the open state by diazoxide and the
plasma membrane depolarised by high KC1 concentration to increase [Ca2+]i. This
demonstrated that glucose could stimulate insulin release independently of the Katp
channel in presence of elevated [Ca2+]j. This pathway was referred to as Katp
channel-independent, Ca2+- dependent pathway (37-39). Moreover, glucose was also
found to augment insulin secretion in Ca2+-depleted islets in the complete absence of
extracellular Ca2+ and in absence of any rise in [Ca2+]j (40). This mechanism of
glucose augmentation functioned maximally when protein kinase A (PKA) and
protein kinase C (PKC) in the P-cell were activated simultaneously. This pathway
9+ •
was referred to as Katp channel-independent, Ca -independent pathway.
Substances such as GLP-1 (which activates PKA) (41) and acetylcholine and
cholecystokinin (which activate PKC) (24,33,42) augment glucose-induced insulin
secretion through this mechanism. It required the binding of these agonists with their
receptors on the P cell membrane and activation of G-protein. Apart from their
differential requirement for Ca2+, these two Katp channel-independent pathways
have common characteristics (36); (a) dependence on glucose metabolism, (b) do
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not initiate but only augment insulin release, (c) similar magnitude of glucose-
induced insulin release, (d) similar glucose concentration-response curves, (e)
similar temporal profiles that resemble the second phase of glucose-induced insulin
release, (f) stimulated by metabolisable nutrients other than glucose and (g)
stimulated by free fatty acids.
At what stage in the stimulus-secretion pathway do the Katp channel-independent
pathways become involved in the augmentation of insulin secretion? It has been
proposed that the site of entry is located at the final stages of insulin secretion,
namely, the exocytosis of immediately releasable pool of insulin (36). Thirty years
ago, Grodsky proposed a two-compartmental insulin storage system within the (3 cell
(48). Since then, it has been confirmed that insulin is indeed stored in two pools;
reserve and immediately releasable insulin pool. This was demonstrated by
capacitance measurement of exocytosis (49) and identification of proteins involved
in the docked pool of immediately releasable insulin granule (50). Exocytosis of
immediately releasable pool of insulin is regulated by Ca2+ and GTP independently
(49). Ca2+-dependent augmentation pathway stimulates Ca2+-triggered exocytosis
while Ca2+-independent augmentation pathway stimulates GTP-triggered exocytosis
(36).
It has been proposed that the Katp channel-independent (Ca2+-dependent and
independent) pathways act through a common mechanism to augment glucose-
induced insulin secretion, namely, an increase in the level of cytosolic long chain







Mechanism by which K+atp channel-independent pathway augments insulin secretion.
Glucose metabolism leads to elevation of cytosolic malonyl CoA levels, inhibition of
mitochondrial CPTI and consequent inhibtion of fatty acid oxidation. This results in an
increase in long chain acyl-CoA esters. Abbreviation: CPTI - carnitine palmitoyl¬
transferase I; Fa-CoA - fatty acyl CoA; FFA - free fatty acid
there is an increase in cytosolic malonyl-CoA which inhibits mitochondrial enzyme
carnitine palmitoyltransferase I leading to decreased fatty acid oxidation and
increased cytosolic LC-CoA levels (45). Cytosolic LC-CoA esters then augment
insulin secretion by modulating the activity of enzymes and other transducing
effectors involved in insulin secretion. For example, this can occur through
activation of PKC directly or indirectly via diacylglycerol production (46,47) or
acylation of key proteins in the exocytosis of insulin granule (45).
i
Finally, both Katp channel-dependent and Katp channel-independent (Ca -
dependent and independent) pathways are needed to cause the full effect of glucose-
induced insulin secretion (figure 3). In the in vivo condition, the pancreatic P-cells
are exposed to various secretagogues, hormones, peptides and neurohormonal agents
apart from glucose. These agents exert their influence on insulin secretion via Katp
9+
channel-independent (Ca -dependent and independent) pathways and function
synergistically with Katp channel-dependent pathway to exert the full magnitude of
insulin secretion.
Location and origin of pacemaker activity for oscillatory insulin secretion
After Goodner et al demonstrated oscillatory plasma insulin concentrations, several
possibilities to account for this were considered (6). Oscillations in plasma insulin
concentration could be due to intermittent clearance or secretion of insulin.
However, since the plasma C-peptide concentration also oscillates in phase with
insulin (51), the origin of insulin oscillations was ascribed to pulsatile secretion




Glucose-induced insulin release from p-cell. Full magnitude of insulin secretion requires
augmentation of insulin release from the Katp channel independent pathway.
insulin is intermittent input to islets from the central nervous system and/or
oscillations in the plasma glucose concentration or other circulating secretagogues.
However, as pulsatile insulin release was observed in isolated canine pancreas
perfused with buffer at a constant glucose concentration, clearly, pulsatile insulin
secretion does not require either input from the central nervous system or
oscillations of circulating glucose concentration (10). This insight was reinforced by
the observation that isolated islets of Langerhans exposed to constant glucose
concentration secrete insulin in a pulsatile manner (52). These data suggest that the
pacemaker for pulsatile insulin secretion lies within the pancreas and that it may be
one or more islets of Langerhans. Currently, there are several hypotheses to account
for the pacemaker activity within the pancreas.
(1) Ganglia hypothesis
It has been proposed that intra-pancreatic ganglia and associated nerves may act as a
pacemaker and/or as a co-ordination system to generate oscillatory insulin release
(53). This hypothesis is supported by several observations. Firstly, pancreatic
ganglia and the associated nerves do not degenerate after denervation of the
pancreas suggesting that they possess some form of autonomous function (54).
Secondly, there is a close anatomical relationship between the intrapancreatic
ganglia, associated nerves and islets (55). Histological examination demonstrated
that nerves originating from the ganglia connect both with other ganglia and groups
of islets (56). (3-cell secretion can be modulated by stimuli from nerves derived from
the intrinsic ganglia or from secretion of non-P cells locally in the islet which may
first receive nervous stimulation (57). Thirdly, intra-pancreatic ganglia have been
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shown to display intrinsic electrical rhythmic activity consistent with frequency of
pulsatile insulin secretion (53). Pancreatic ganglia receive innervation from
adrenergic, cholinergic and peptidergic nerves (54). However, as blockade of
adrenergic and muscarinic receptors did not affect insulin secretory pattern both in
canine pancreas in vitro (10) and humans in vivo (58), peptidergic nerves might be
the principal mediator of insulin secretion. It has been suggested that post-synaptic
nicotinic receptors at the ganglia might be the principal regulator and co-ordinator of
insulin secretion (59).
However, there are also arguments against a central role of intrapancreatic ganglia
as the pacemaker for pulsatile insulin secretion. Pulsatile insulin secretion occurs in
perifused single islets (12,13) and in single P-cells (14) revealing that p-cell has the
properties to be an independent pacemaker. Currently, there are two hypotheses to
account for the origin of oscillations in P-cells; oscillations in cytosolic
i ^ i
Ca concentration, [Ca ]j and oscillations in glycolysis.
(2) Cytosolic [Ca2+J,- oscillation hypothesis
This hypothesis proposes that oscillations in cytosolic [Ca2+]i drive the oscillations
in insulin secretion. Following glucose stimulation, oscillations in membrane
potential lead to intermittent Ca2+influx through voltage-gated Ca2+ channels
(60,61). This periodic influx of Ca2+ leads to oscillations in cytosolic [Ca2+]j and
insulin secretion (62,63). The regulatory role of cytosolic [Ca2+]i in insulin secretion
• 2~p • •is well-established. It has been shown that Ca omission (64,65) or addition of
9+
voltage-dependent Ca channel blocker (66) abolishes glucose-stimulated insulin
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secretion. Furthermore, apart from glucose-induced elevation in cytoplasmic [Ca2+]j
with subsequent release of insulin from (3-cells (62,63), elevation in the external
Ca2+ concentration has been shown to stimulate insulin secretion from permeabilized
(3-cells (67). The regulatory role of cytosolic [Ca2+]j was further supported by the
demonstration of the synchronous oscillations of cytosolic [Ca2+]j and insulin
secretion from pancreatic islets (68). More recently, the issue of synchronicity
between cytosolic [Ca2+]j and insulin secretion oscillations was further strengthened
when Jonas et al (63) demonstrated a close temporal and quantitative relationship
between [Ca2+]j and insulin secretion in mouse pancreatic (3-cells. Synchronous
oscillatory insulin secretion occur only when [Ca2+]i oscillates. When oscillations in
[Ca2+]j were abolished by continuous depolarisation with 30 mmol/L K+ resulting in
9+ • •
sustained elevation in [Ca ]i, no oscillations in insulin secretion was seen. Further
support for the regulatory role of cytosolic [Ca2+]j came from the observation that
• . • 9"f •
imposed oscillations of free Ca in permeabilised insulin-secreting cells triggered
oscillations in insulin secretion in absence of any metabolic oscillation (69).
However, in order to generate oscillations, a feedback system must exist to maintain
cycles of depolarisation followed by repolarisation of membrane potential. Two
mechanisms have been proposed;
(a) Feedback of[Ca ], on mitochondrial respiration (figure 4)
This model depends on feedback loop between [Ca2+]j, mitochondrial respiration, its
ATP production and the subsequent effect on ATP/ADP ratio and K+atp channel




2+Model of feedback control of Ca on mitochondrial metabolism and ATP/ADP ratio in P-
cells. Glucose metabolism increases the ATP/ADP ratio. This leads to closure of Katp
channel (1) with depolarisation of the plasma membrane (2) and opening of the voltage-
dependent Ca2+ channel. Influx of extracellular Ca2+ (3) causes a rise in cytoplasmic [Ca2+]i
which triggers exocytosis of insulin granules (4). With elevation of cytoplasmic [Ca2+]i,
there is increased uptake of Ca2r into the mitochondria (5) which leads to decrease in the
mitochondrial membrane potential and reduction in ATP production and ATP/ADP ratio
(6). This leads to reopening of the Katp channel, membrane repolarisation, arrest of Ca2T
influx, lowering of [Ca2+]j and restoration of a high ATP/ADP ratio to initiate a new cycle.
Abbreviation: T7 - membrane potential of P-cell; T'm - membrane potential ofmitochondria
by mitochondria resulting in decrease in mitochondrial membrane potential and
inhibition of ATP synthesis. This leads to a reduction in the ATP/ADP ratio causing
the K+atp channels to open leading to membrane repolarisation and inactivation of
the voltage-gated Ca2+ channels. This causes [Ca2+]j to decrease, thus, relieving its
inhibition on mitochondrial respiration and ATP production. ATP/ADP ratio rises
• • 94-
again to generate another cycle of membrane potential and [Ca ]; changes. This
could trigger oscillations of the ATP/ADP ratio and its subsequent effect on K+-ATP
2~bchannel activity, membrane potential, [Ca ]j and insulin secretion through feedback
inhibition by Ca2+ ofmitochondrial ATP production. However, experimental data do
not support this hypothesis (71).
(b) Feedback of [Ca2]: on if-ATP channel activity (figure 5)
Alternatively, repolarisation may be achieved by feedback of [Ca2+]i on K+atp
channel activity via modulation of ATP/ADP ratio. Once [Ca2+]j is elevated, further
2™f" "1"rise is prevented by the inhibitory actions of Ca on the activity of K atp channels
(72). A recent study showed that this might be achieved via changes in ATP
• • 9+ •
consumption (73). The rise in [Ca ]i results in lesser degree of rise in the ATP/ADP
ratio compared to situation where [Ca2+]i is prevented from rising through blockade
of extracellular Ca2+ entry (73). Elevation in [Ca2+]j causes simultaneous increment
in ATP production through stimulation of Ca2+-dependent mitochondrial
dehydrogenases (74) and increment in ATP consumption possibly through
membrane ATPase (75). However, there is net reduction ATP concentration as the
ATP consumption occurs at a faster rate than its production (73). This leads to




Model of feedback control of Ca2 on the Katp channel activity via modulation of ATP
consumption and ATP/ADP ratio in P-cells Glucose metabolism increases the ATP/ADP
ratio. This leads to closure ofKatp channel (1) with depolarisation of the plasma membrane
(2) and opening of the voltage-dependent Ca2+ channel. Influx of extracellular Ca2 (3)
causes a rise in cytoplasmic [Cajj which, in addition to triggering exocytosis of insulin
granules (4), exerts an effect that influence the ATP/ADP ratio in opposite direction. Via
activation of mitochondrial dehydrogenases, Ca2~ promotes ATP production (5) and also
simultaneously increases ATP consumption (6). The net result is reduction in ATP/ADP
ratio, leading to reopening of the Katp channel, membrane repolarisation, arrest of Ca2
influx, lowering of [Ca2+]i and restoration of a high ATP/ADP ratio to initiate a new cycle.
Abbreviation: ¥ - membrane potential of P-cell
repolarisation, inactivation of voltage-gated Ca2+ channels, reduction in [Ca2+]j and
eventual restoration of a high ATP/ADP ratio to initiate a new cycle.
However, data exist that challenges the role of [Ca2+]j oscillations as regulator of
oscillatory insulin secretion which argue for the role of P-cell metabolism as the
pacemaker. Oscillatory insulin secretion has been observed in these situations: (a)
low and non-oscillatory [Ca2+]j resulting from islets being exposed to non-
stimulatory glucose concentration level (76); (b) sustained, elevated and non-
oscillatory [Ca2+]i when islets were exposed to sustained depolarisation by high K+
concentration or tolbutamide (77) and (c) P-cell membrane potential is 'clamped'
with exposure of islets to diazoxide (76,78). Furthermore, oscillatory K+atp channel
activity has been observed in presence of closed voltage-gated Ca2+ channels
suggesting the occurrence of fluctuations in ATP production resulting from
glycolytic oscillation (79).
(3) Metabolic hypothesis
The proponents of this hypothesis propose that oscillation of glycolysis in P-cells is
the pacemaker for pulsatile insulin secretion. Glycolytic oscillations depend on
interaction between glucokinase, phosphofructokinase M isoenzyme and ATP/ADP
ratio (80). Following glucose uptake into P-cell, the rapid flux through glucokinase
generates ADP and causes a transient decrease in ATP-ADP ratio. This has the dual
effect of increasing glycolysis via PFK-M activation and stimulating mitochondrial
metabolism via activation of mitochondrial dehydrogenases and the respiratory
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chain. This leads to a rise in ATP and ATP/ADP ratio resulting in the closure of the
K+atp channels and inhibition of glycolysis and mitochondrial respiration until a rise
in ADP reactivates metabolism and initiates another cycle. Furthermore,
phosphofructokinase M isoenzyme (PFK-M) which is responsible for generating
oscillations in glycolysis in skeletal muscle extracts, is also found in p-cell (81). The
importance of PFK-M is suggested by studies in humans with a genetic deficiency
of this isoenzyme, in whom oscillations in insulin secretion are impaired (82,83).
Oscillations in glycolysis is a widespread phenomenon and have been shown in
skeletal muscle extracts (84), yeast cells and extracts (85), heart extracts (86) and
ascites tumour cells (87). Therefore, it was not surprising to find that glycolytic
oscillations also occur in pancreatic islets (88) and single P-cells (89). In support of
the occurrence of glycolytic oscillations in P-cells, the following observations have
been made; (a) oscillations in lactate release occur with the same periodicity as
insulin secretion in glucose-stimulated pancreatic islets (88), (b) oscillations of
similar frequency in O2 consumption, [Ca2+]i and insulin secretion have been
observed following glucose stimulation of islets (90), (c) Oscillations in NADH
have been observed in cell-free islet extracts exposed to glucose and glycolytic
cofactors (91) and (d) oscillations in ATP/ADP ratio (92) and NADPH (74) have
been demonstrated in glucose-stimulated islets.
It has been argued that oscillations in [Ca2+]i are not necessarily driven by
oscillations in P-cell metabolism. Since Ca2+ can activate mitochondrial
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dehydrogenase enzymes to stimulate mitochondrial respiration (74), it was proposed
that metabolic oscillations is the consequence of rather than the cause of oscillations
in [Ca2+]i. However, it was shown that the rise in NADPH (89) and ATP/ADP ratio
(92) occur before the rise in [Ca2+]i implying that changes in [Ca2+]j is secondary to
glucose metabolism. Furthermore, glucose-stimulated rise in ATP/ADP ratio was
not prevented by Ca2+channel blockers that prevent the rise in [Ca2+]j (93). In
9+
conditions of non-stimulatory glucose concentration where [Ca ]j is low without the
2 j jstimulated entry of extracellular Ca , cyclic variations in the K Atp channel activity
has been demonstrated implying that [Ca2+]j oscillations have a metabolic origin
(76).
However, the argument against the metabolic hypothesis was shown by the lack of
oscillations in NADPH following stimulation of mouse islets with glucose whilst
synchronous oscillations occur in both [Ca2+]j and membrane potential (94). Since
NADPH is a reflection of P-cell metabolism and its pattern of rise was monophasic
• • • 9+
and non-oscillatory, it was felt that the changes in [Ca ]; and membrane potential is
unlikely to result from oscillations in glucose metabolism.
(4) Integration ofthe ganglia, membrane and metabolic hypothesis
An alternative explanation to account for the pacemaker activity generating pulsatile
insulin release is that both glycolysis and membrane potential oscillations are
important and that in vivo, they are inter-dependent. Indeed, it would be hard to
imagine how these oscillations could be distinct. P-cell metabolism can drive
oscillations in membrane potential and [Ca2+]j. Alternatively, oscillations in
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membrane potential and [Ca2+]j can drive oscillations in p-cell metabolism via the
94-
influence of Ca on mitochondrial dehydrogenases and through the subsequent
changes in ATP/ADP ratio on glycolysis and mitochondrial metabolism. It is clear
that both metabolic and membrane oscillations are intimately linked to each other.
Therefore, it is possible that both oscillate in synchrony to augment and optimise the
efficacy of the machinery involved in insulin secretion.
What is the role of intrapancreatic ganglia? Although it may not be necessary for the
generation of insulin secretion, it may play a role in fine tuning the P-cell oscillatory
behaviour via input from the nervous system. This is supported by the observation
that the period of insulin oscillations was altered following truncal vagotomy (95).
Furthermore, it can facilitate the spread of electrical activity between pancreatic
islets which is required for insulin secretion to occur. In conclusion, it is conceivable
that membrane, metabolic and intrapancreatic ganglia are involved simultaneously
in the generation and regulation of the pulsatility of insulin secretion.
Synchronisation of oscillatory insulin secretion
There are around one million islets in a human pancreas and each islet contains
about 2500 p cells (96). Yet, oscillatory insulin secretion is co-ordinated both in vivo
and in vitro. Therefore, there is a mechanism where the spread of electrical activity
in the form of depolarisation wave is synchronised throughout the one million islets.
In an intact pancreas, intrapancreatic neural network may play an important role in
synchronising the transmission of the electrical wave of depolarisation. This
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argument gains support from studies with transplanted islets showing islet to islet
innervation is required to achieve co-ordinate pulsatile insulin secretion (97). That
extrinsic neural input does not appear to be important in coordinating oscillatory
insulin secretion is based upon the observation that patients with a transplanted
pancreas have pulsatile insulin secretion (98,99). Furthermore, isolated perfused
pancreas preparation without any extrinsic neural network secreted insulin in
pulsatile fashion (10).
Groups of perifused islets (without interconnecting nerve fibers) also showed
pulsatile insulin secretion (11,12). It has been postulated that a diffusible factor
secreted by the islets might co-ordinate the synchronisation process. Various
substances have been proposed such as ATP, lactate, pyruvate and insulin but have
been proven to be negative (100). At present, the diffusible substance remains
unknown and its hypothesis unproven. Alternatively, electrical coupling of several
adjacent islets through the perfusion barrier may synchronise the secretion since the
P-cell is an electrically excitable tissue and generates electrical current. Careful
inspection of insulin release by perifused islets shows that only -50% of insulin (or
less) (12) is released in co-ordinate pulses whilst single islets release -100% of
insulin in pulses (101,102). This observation suggests that synchronisation is far
from complete in these preparation.
Pulsatile insulin secretion is also observed in perifused single pancreatic islets
(101,102). It is known that integrated secretory response of intact pancreatic islet is
greater than that of dispersed islet cells and that reaggregation improves secretory
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responsiveness suggesting that intra-islet interactions are essential for normal
secretory responses (103-106). The nature of these intra-islet interactions remains
uncertain. It has been proposed that the paracrine effects of glucagon (106) or
glucagon-like peptide 1 (107) which act through the cAMP-dependent protein kinase
A (PKA) pathway might be responsible. However, the paracrine effects may not
have a major influence on islet cell function since inhibition of PKA pathway in
intact islets did not affect basal or glucose-induced insulin secretion (108,109).
Direct contact between P-cells appears to be necessary to enhance nutrient-induced
insulin secretion (105,110). Within an islet, P-cells are connected by gap junctions
composed of the protein connexin 43 (Cx43) (111) and are electrically coupled
(112). This raises the possibility that gap junction communication between p-cells
may play a role in co-ordinating the heterogeneous response of individual P-cells to
produce the observed integrated secretory response of the whole islet (113). This
important role of gap junction is further supported by the following observations; (a)
gap junction blocker, heptanol, has been shown to abolish glucose-induced insulin
secretion from intact islets but not from single P cells (114); (b) gap junctions and
coupling increase between p-cells during sustained stimulation of insulin secretion
(115) and (c) isolated p-cells showed impaired secretion which improved after re-
establishment of gap junctions (116). Apart from communication between P-cells,
interaction between p and non-P cells within the microenvironment of the islet
appears to be important also (117).
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Taking a holistic approach, one could envisage the initiation of the electrical wave
of depolarisation from the [3-cells and/or intra-pancreatic ganglia with its subsequent
transmission through each individual (3-cell via gap junctions with concomitant
interaction occurring between (3-cells and non-P cells and subsequently involving
the adjacent and distant islets via the intra-pancreatic neural network in the process
of electrical coupling of the whole pancreas to create a co-ordinated secretory burst
with its frequency being determined by the pancreatic pacemaker which is
modulated, perhaps, by external influence such as extrinsic pancreatic neural
connections.
Regulation of insulin secretion
Since insulin is secreted in discrete bursts, establishing an accurate method for the
detection and quantification of insulin secretory bursts is crucial to the
understanding of the regulation of pulsatile insulin secretion. Quantification of the
pulsatile insulin secretion presents several difficulties. Firstly, the frequency of
insulin secretory bursts (pulse interval ~ 5-8 mins) is several-fold greater than that of
the more extensively studied hypothalamo-pituitary hormones (pulse interval ~ 60
mins). Secondly, insulin is secreted into the portal circulation and undergoes
significant hepatic extraction and waveform damping before entry into the systemic
circulation. Thirdly, whereas there are well-established methods available to
quantify secretion rate of the pituitary hormone (118), there are no validated
methods to quantify pulsatile insulin secretion. However, these difficulties were
recently overcome by employing a canine model in which pulsatile insulin secretion
was measured directly in the portal vein by catheterisation across the pancreas (8).
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This study provided the opportunity to validate an established deconvolution
program for the measurement of pulsatile insulin secretion and applied this
technique to quantify pulsatile insulin secretion from peripheral blood
measurements. Subsequently, this method of deconvolution analysis was validated
for the quantification of pulsatile insulin secretion from peripheral blood
measurements in human beings (15).
By employing the validated deconvolution method to quantify pulsatile insulin
secretion in vivo, it was subsequently found that majority of insulin was secreted in
the pulsatile component (at least 70%) in the fasting phase (8,15). Furthermore, the
regulation of insulin secretion occurred via modulation of the pulsatile component
predominantly through regulation of its secretory burst mass. For example, in a
canine model, the increment in insulin secretion after glucose ingestion was
achieved by a -400% increase in insulin secretory burst mass and -40% increase in
burst frequency (16). Furthermore, other studies showed that inhibition of insulin
secretion via somatostatin (in dogs) (17) and IGF-1 (in humans) (119) and
conversely, stimulation of insulin secretion via GLP-1 (in humans) (19) and
sulphonylurea (in dogs) (18), were achieved predominantly by inhibition and
amplification of insulin secretory burst mass respectively. Although deconvolution
program has yet to be validated for the detection and quantification of pulsatile
insulin secretion from perifused pancreatic islets, studies have shown that perifused
groups of islets (90) and single islets (101) exposed to elevated levels of glucose
augment their insulin secretion via amplification of the pulse amplitude. This raised
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the possibility that, at the level of pancreatic islets, the regulation of insulin secretion
is most likely to occur through the modulation of its pulsatile component.
Since the regulation of insulin secretion is predominantly achieved by changes in its
secretory burst mass, the question arises, what is the mechanism by which the burst
mass is altered? Insulin secretory burst mass may be regulated by the number of (3-
cells per islet recruited per burst and/or the size of the immediately releasable insulin
pool secreted by each (3-cell per burst. The former may occur via recruitment of P-
cells that are quiescent at low glucose levels in conditions of raised glucose
concentration (90). This model was proposed by Pipeleers et al (120) who reported
that there is heterogeneity in glucose sensitivity at different glucose concentration
level among the P-cells. Alternatively, the size of immediately releasable insulin
pool can be modulated. GLP-1 is thought to act via this mechanism by increasing
the sensitivity of P-cells to the prevailing intracellular ATP concentrations resulting
in amplification of insulin secretion from immediately releasable insulin pool
following depolarisation (19). Sulphonylurea is also thought to act similarly by
increasing the proportion of pre-existing insulin granules that undergo exocytosis
(18).
Whilst the frequency of insulin secretory burst remains relatively unchanged as
opposed to the pulse mass or amplitude (16-19,68), it implies that the intrinsic
rhythm of the pancreatic pacemaker which generates pulsatile insulin secretion is
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resistant to both stimulatory and inhibitory stimuli. Thus, the intra-pancreatic
pacemaker activity is a remarkably stable phenomenon.
Physiological relevance in health
In humans, the pituitary hormones are secreted in a pulsatile manner (1,2). Since the
pancreas forms part of the endocrine system, it is not surprising that insulin is
secreted in pulsatile manner also. The biological importance of this inherent pattern
of secretion is to prevent receptor down-regulation and thus, enhance the hormone
effect on target tissues. Insulin receptors have been shown to down-regulate when
exposed to high steady-state insulin concentrations in vitro (121) and in vivo (122).
The greater hypoglycaemic effect of pulsatile insulin delivery in human subjects was
first shown by Matthews et al (123). Subsequently, this observation was confirmed
by other studies and the hypoglycaemic action was mediated through suppression of
hepatic glucose release (124-126). In these studies, insulin was infused into the
peripheral circulation.
As insulin is secreted directly into the portal vein, it is plausible that it acts directly
to suppress hepatic glucose production (127). Recently, this direct inhibitory action
of insulin on hepatic glucose production was demonstrated in human beings (128).
Hepatic insulin action and hepatic insulin clearance are mediated through binding of
insulin to its receptor on hepatocyte plasma membrane (129). Following the binding
of insulin to its hepatic receptor, the complex of bound insulin and its receptor is
internalised. Intracellular signalling is generated and initiates the action of insulin on
glucose metabolism and insulin clearance within the liver. The receptor is then
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recycled and reinserted into the hepatocyte plasma membrane. The duration of this
receptor recycling is reported to be 5-10 minutes (130). This is similar to the
physiological range of insulin pulse frequency, thus, maintaining the optimal
number of the hepatic insulin receptors to bind with the insulin molecules arriving as
pulses. In addition, pulse amplitude plays an important role in determining hepatic
sensitivity to insulin action. There is a correlation between the pulse amplitude and
hepatic insulin clearance (17) and the amount of hepatic insulin receptors bound and
internalised (130). It is plausible that hepatocytes preferentially bind insulin
delivered in pulses that create a high peak concentration typically seen within the
portal circulation.
Pulsatile insulin secretion has been shown to be abnormal in type 2 diabetes subjects
(20). Since the magnitude of insulin pulses in the peripheral circulation is attenuated
in this condition, it is likely that the liver in these patients is exposed to even more
attenuated oscillations in insulin pulse amplitude. It is plausible that the diminished
insulin pulses in the portal circulation may contribute to the hepatic insulin
resistance and excessive hepatic glucose production, the inherent features of type 2
diabetes mellitus (131). Support for this notion is derived from the observation that
hepatic clearance of portal vein insulin is related to the pulse amplitude of the
insulin concentration wavefront presented to the liver in a canine model (17).
Reduction in the number of insulin molecules bound to their hepatic receptors and
internalised to exert its biological function could be the mechanism. However, the
direct effect of portal insulin pulse amplitude modulation on hepatic glucose release
in human beings remains to be studied.
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Potential causes for abnormal oscillatory insulin secretion
Many potential causes for the impaired pulsatile insulin secretion have been
proposed. One possible cause is loss of pacemaker function. However, the presence
of pulsatile insulin secretion in patients with type 2 diabetes mellitus (20) and in
groups of perifused islets from these patients in vitro (132) argue against this point.
Alternatively, defects in intra- or interislet communication system may account for
the abnormal oscillatory insulin secretion. Defects in intraislet communication
between P-cells may be caused by deposition of islet amyloid between P-cells
resulting in disruption of gap junction communication which play important role in
synchronising insulin secretion (133). Deposition of cytotoxic human amyloid can
be enhanced by the increased rate of amyloid secretion induced by insulin resistance
or decreased availability and/or function of heat-shock proteins (133). Recently, it
has been shown that cytotoxic human amyloid induce P-cell death by apoptosis and
pore formation in the cell membrane (134,135). It is conceivable that loss of P-cells,
especially the subpopulation of 'pacemaker' cells, can lead to disruption of the
oscillatory secretion. Another potential cause is the disruption of intra-pancreatic
neural network. Although autonomic neuropathy is a well-known late complication
of diabetes (136), there is no evidence this is present prior to the onset of clinical
diabetes when the abnormal oscillatory insulin secretion is already present.
Therefore, it is unlikely that this factor play a mechanistically important role in the
early stages of type 2 DM. Another potential cause is the depletion of immediately
releasable pool of insulin so that when a wave of depolarisation reaches the p-cell,
there is sub-optimal mass of insulin available to be discharged. Recently, it has been
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shown that the pool of immediately releasable insulin is responsible for the first
phase insulin secretion (137). The observation of diminished first phase insulin
secretion in type 2 diabetes mellitus (138) supports the hypothesis of depleted
insulin pool. This hypothesis of impaired insulin secretion as a consequence of
depleted insulin stores is one of the issues addressed in this MD thesis and will be
discussed in more detail in the following section.
Effect of p-cell rest on insulin secretion
Pancreatic P-cell mass is reduced by at least 50-60% in type 2 diabetes mellitus
(139-141). Hence, it is plausible that the reduction in P-cell mass (and insulin stores)
might contribute to defective insulin secretion in type 2 diabetes. Following
reduction in P-cell mass, there is an increased secretory demand on the remaining P-
cells to compensate for this loss. This enhanced P-cell secretory function is further
augmented by the presence of peripheral insulin resistance and hyperglycaemia.
Eventually, this state of chronic over-stimulation of p-cell secretory function
exceeds its insulin synthesis capacity leading to depletion of insulin stores resulting
in impaired glucose-induced insulin secretion.
Most of the evidence to support this hypothesis came from animal studies. Rat islets
exposed to high glucose concentrations had impaired insulin secretion and reduced
insulin stores (142). Surgically-reduced P-cell mass as a model of type 2 diabetes i.e.
90% pancreatectomised Sprague-Dawley rats developed hyperglycaemia which was
associated with impaired insulin secretion and depleted insulin stores (143). Normal
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Sprague-Dawley rats exposed to tolbutamide to chronically stimulate insulin
secretion in presence of normoglycaemia also led to depletion of insulin stores and
impaired insulin secretion (144). In humans, healthy non-diabetic subjects who
underwent hemipancreatectomy for the purpose of organ donation, had raised
fasting plasma glucose, impaired insulin secretion, abnormal glucose tolerance and
reduced maximal acute insulin response (AIRmax) (145,146). Irrespective of the
mode of stimulation of insulin secretion (whether it is hyperglycaemia or non-
hyperglycaemia-induced), the end result was similar; impaired glucose-induced
insulin secretion with depleted insulin content.
Further evidence to support this concept came from studies looking into the cause of
relative and absolute hyperproinsulinaemia in Type 2 diabetes. Metabolic clearance
of proinsulin is unchanged in subjects with type 2 diabetes (147,148), indicating that
hypersecretion of proinsulin accounts for the raised plasma proinsulin levels
(149,150). Two hypotheses were proposed to explain the aetiology for the
hyperproinsulinaemia. First, a defect in the enzymatic proinsulin processing
mechanism within the (3-cell was suggested (147). This defect could occur in the
post-translational modification of proinsulin molecule leading to proinsulin-rich
granule. Alternatively, a heightened demand on insulin secretion from
hyperglycaemia can deplete the P-cell of mature granules, resulting in an enriched
population of immature (proinsulin-rich) granules for secretion (151). In a study by
Alarcon et al, it was shown that normal rats made hyperglycaemic with 48-hr
glucose infusions had a raised percentage of pancreatic proinsulin to insulin ratio
(151). The pancreatic insulin content was reduced whilst the proinsulin content
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remained unchanged. Moreover, there was a decrease in the islet content of
proinsulin conversion enzymes, PC2, PC3 and CP-H. It was observed that the
release of PC2, PC3 and CP-H enzymes was increased along with insulin and there
was no associated deficiency in the biosynthesis of PC2, PC3, CP-H and proinsulin.
Proinsulin conversion rate remained unaffected by the hyperglycaemic condition.
These observations suggested that hyperproinsulinaemia induced by hyperglycaemia
is likely to result from increased p-cell demand rather than a defect in the proinsulin
processing enzyme.
If this concept of chronic over-stimulation of P-cell secretion with subsequent
defective glucose-induced insulin secretion is valid, then 'resting' the pancreas by
lowering its insulin secretory demand should result in improved endogenous insulin
secretion and content. P-cell rest can be achieved by two ways; (1) indirectly by
reducing the glucose load on the pancreas through normalisation of the plasma
glucose concentration, (2) directly by pharmacologically-induced inhibition of P-cell
insulin secretion by agents such as diazoxide or somatostatin. There is evidence
from both human and animal models that these two methods of P-cell rest lead to
improved insulin secretion. Normalising plasma glucose in type 2 diabetic subjects
by intensive insulin treatment led to improvement of first (152) and second (153)
phase insulin secretion. Furthermore, treatment by diet and sulphonylurea
medication to achieve normal glucose level also led to improvement in endogenous
insulin secretion in subjects with Type 2 diabetes (154,155). Hales et al (156)
administered oral diazoxide to subjects with Type 2 diabetes for 5 days and showed
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improvement in first phase insulin secretion. This observation was supported by a
study by Laedtke et al (157) who infused somatostatin overnight to 'rest' the p-cells
which subsequently resulted in the restoration of first phase and pulsatile insulin
secretion. However, these human studies do not demonstrate the effect of (3-cell rest
on the pancreatic insulin content. This question was addressed by Leahy et al (143)
who administered diazoxide to a surgically-reduced P-cell mass model of type 2
diabetes i.e. 90% pancreatectomised Sprague-Dawley rats. This study showed that
the enhancement in pancreatic insulin secretion was associated with an increment in
pancreatic insulin stores, normalisation of plasma glucose concentration and oral
glucose tolerance demonstrating the beneficial effects of p-cell rest on its function
was mediated by restoration of pancreatic insulin content.
Further support for the concept of P-cell dysfunction as a consequence of
hyperstimulation came from studies that studied the effects of P-cell rest on
hyperproinsulinaemia in hyperglycaemic condition. In normal rats made
hyperglycaemic by glucose infusion, diazoxide resulted in the reduction of the
pancreatic proinsulin/insulin ratio by attenuating the fall of pancreatic insulin
content leading to greater quantity of mature (insulin-rich) granules (150). In human
islets exposed to high glucose concentration, diazoxide also reduced the
proinsulin/insulin ratio and increased the islet insulin content (158). In subjects with
type 2 diabetes, proinsulin/insulin ratio was normalised in conditions of euglycaemia
achieved by diet or sulphonylurea medication (154).
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The working model of chronic stimulation leading to (3 cell dysfunction and
impaired insulin secretion is depicted in figure 6. With the reduction in (3 cell mass,
hyperglycaemia ensues. This stimulates the residual p cells to secrete insulin
excessively, perhaps, by increasing p cell sensitivity via upregulated activity of
hexokinase (159) or hyperactivation of the entire P cell population with the loss of
the intercellular heterogeneity (142). Excessive insulin secretion outstrips insulin
synthesis leading to reduction in insulin stores, mediating two functional
consequences: reduced insulin secretion and relative hyperproinsulinaemia (raised
proinsulin to insulin ratio).
MP projects
From the discussion above, four related projects were performed to address the
pattern of insulin secretion and the specific mechanism by which P-cell positively
influences these:
Project one:
Direct measurement of the pattern of insulin release in the portal vein in human
subjects in the basal state and in response to glucose stimulation. This will be
achieved by using the validated method of deconvolution to analyse the pattern of
insulin secretion.
Project two:
Examination of the effects of acute inhibition of insulin secretion by diazoxide on
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Figure 6
Pathophysiology of impaired glucose-induced insulin secretion from the loss of (3-cell mass.
Project three:
Development and validation of a method to quantify pulsatile insulin secretion by
cultured human pancreatic islets in the perifusion system.
Project four:
Application of the system developed and validated in project three to test the
hypothesis that transient (3-cell rest in human pancreatic islets induced by diazoxide
attenuates the loss of first phase, second phase and pulsatile insulin secretion caused
by culture of the islets in glucose concentration comparable to those seen in Type 2
diabetes and to examine the effect on islet insulin content on insulin release.
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Chapter 2
Direct measurement of pulsatile insulin secretion from the portal vein in
human subjects
Introduction
Insulin is secreted in high-frequency pulses (1). This pattern of insulin secretion has been
shown to be abnormal in subjects with Type 2 diabetes mellitus (2) and their first-degree
relatives (3) and patients at risk of developing Type 1 diabetes (4). However, quantification
of pulsatile insulin secretion is complex. Insulin pulses are secreted into the portal
circulation and undergo significant hepatic extraction and waveform damping before
entering the systemic circulation (5). We previously developed a canine model of direct
portal vein catheterisation to overcome this problem (6), and reported that sampling from
the systemic circulation resulted in an underestimate of both the frequency of insulin pulses
as well as the calculated proportion of insulin released in the pulsatile mode (5). Inevitably
studies of pulsatile secretion in humans have been confined to the systemic circulation (2-
4,7-12). Initially such studies reported a pulse frequency of 15-20 minutes (2-4,7,8) but
more recently a pulse frequency of ~6 minutes has been suggested (11,12). We have
speculated that these differences may reflect the greater sensitivity of novel insulin assays
applied in the latter studies, and that the true frequency of insulin pulses delivered into the
portal circulation in humans may be 6-8 minutes. The latter would be comparable to the
frequency observed in the isolated perfused pancreas (13) as well as the perifused islets (14-
15).
In the current study, we applied a validated deconvolution technique for quantifying
pulsatile insulin secretion to plasma insulin concentration profiles obtained simultaneously
from the portal vein and the systemic circulation in human subjects with stable compensated
hepatic cirrhosis and an in situ transjugular intrahepatic portasystemic stent shunt (TIPSS)
(16). The TIPSS catheter allowed relatively noninvasive high-frequency sampling of blood
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from the portal vein in conscious human subjects. Pulsatile insulin secretion was quantified
in the fasting basal state as well as during a hyperglycemic clamp study.
Using this protocol we sought to address the following questions. First, is the frequency of
pulsatile insulin secretion in humans (observed by direct sampling from the portal
circulation) comparable with the frequency reported previously from studies in isolated
islets, the isolated pancreas and in vivo by sampling from the portal vein in dogs (interpulse
interval -6-8 minutes) or -15-20 minutes as reported in some studies using the systemic
sampling site in humans? Second, does insulin secretion in humans match the dynamics
reported in dogs based on direct portal vein sampling, wherein the majority of insulin is
secreted in discrete bursts? And third, does hyperglycemia in the human (as in the dog)
enhance insulin secretion through the specific mechanism of augmenting the mass of insulin
bursts? Finally, we examined whether the amplitude of the insulin-concentration wavefront
to which the liver is exposed in humans approaches that observed in the portal vein of dogs
(5,6).
Methods and material
Study subjects and design (tables 1 and 2)
This study was approved by the Lothian Ethics Committee and all volunteers provided
informed written consent. Inclusion criteria were patients with a patent TIPSS and known
stable compensated liver disease. Patients were deliberately selected to represent those in
which the predominant liver-related problem was cirrhosis and portal vein hypertension
treated with a transjugular intrahepatic portosystemic stent shunt (TIPSS), rather than
progressive liver failure or active hepatic inflammation. Exclusion criteria include
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Table 1: Patient characteristics
Case Age Sex Weight (kg) BMI FPG Glucose
(years) (kg/m2) (3.9 - 6.1) mmol/L tolerance
1 58 F 60 23 4.4 Normal
2 61 M 71 22 5 Impaired
3 43 M 71 24 4 Impaired
4 61 M 100 33 5.8 Normal
5 54 M 117 36 5.4 Impaired
Legend
FPG= fasting plasma glucose; M= male; F= female, BMI = body mass index
Table 2: Liver function studies
Type of Alk phos GGT Bilirubin Albumin ALT INR
Cirrhosis (40-125 (5-35 u/L) (2-17 uM) (36-47 g/L) (10-40 (2-4.5)
u/L) uL)
alcoholic 125 124 56 32 14 1.4
alcoholic 80 20 17 43 27 1
alcoholic 146 100 42 34 56 1.3
alcoholic 135 61 147 35 35 1.7
alcoholic 92 54 17 41 33 1.2
Legend
ALT alanine amino transferase
Alk Phos alkaline phosphatase
GGT gamma-glutamyl trasferase
INR International Normalized Ratio
decompensated liver dysfunction, diabetes mellitus, a thrombosed stent, and/or a prolonged
prothrombin time. All patients were studied 1-2 weeks prior to the TIPSS study to have a 75
gram oral glucose tolerance test performed to exclude diabetes mellitus. Of six subjects
screened, one was excluded from the study because of diabetes.
Five patients with in-situ TIPSS were studied immediately after a routine follow-up
assessment of the patency of their TIPSS. For this purpose patients were admitted overnight
into the Royal Infirmary of Edinburgh and after an overnight fast a catheter placed in the
right jugular vein and under ultrasound guidance passed through the TIPSS into the portal
circulation. The purpose of the clinical assessment was to ensure that the TIPSS remained
patent. Once this had been confirmed, a catheter was inserted via the right internal jugular
introducer sheath into the portal vein to allow the present study to be completed.
Study protocol
All study subjects were admitted to the University of Edinburgh Wellcome Trust Clinical
Research Facility at the Royal Infirmary of Edinburgh the night prior to the study and
remained fasting overnight. On the morning of the study, each subject underwent TIPSS
portogram performed by a radiologist as part of the routine follow-up assessment of the
patency of the in-situ TIPSS and the sampling catheter placed in the portal vein at the end of
this procedure.
A peripheral indwelling sampling catheter was also inserted into a dorsal hand vein and the
hand was warmed to 40°C by an electric blanket to permit subsequent sampling of
arterialized blood. An intravenous catheter was also placed in an antecubital vein in the
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contralateral arm and infused with saline at 30 ml/hour. Once all the catheters were in place
there was a 45 minute rest period prior to commencement of the protocol at -10:00 am. At
protocol time 0-40 minutes, simultaneous intensive 1-minute sampling of arterialized blood
and portal vein blood were performed to obtain the minutely insulin concentration profile at
each site in the fasting state. At protocol time 40 min, a hyperglycaemic clamp was
commenced with the object of raising the arterialized plasma glucose concentration to 8-9
mmol/1. This was achieved by infusion of a variable rate glucose infusion (Dextrose 50%)
administered by a programmable infusion pump (Harvard Infusion Pumps, Ayer, MA) on¬
line to a personal computer. Arterialized blood was sampled at 5-minute intervals and the
plasma glucose measured within 2 minutes. Steady state hyperglycemia was achieved by
protocol time 80 minutes (40 minutes after the clamp was begun) and then the second
sampling period began. From protocol time 80-120 minutes, blood was sampled at one-
minute intervals from the arterialized peripheral vein catheter and the portal vein catheter to
determine the insulin concentration profile during the hyperglycemic clamp. Portal vein
sampling was completed in all 5 study subjects in both the basal and hyperglycemic
sampling periods. Arterialized sampling was completed in four of the five subjects, the
peripheral sampling catheter was unreliable in the remaining subject. In two subjects portal
vein blood flow was measured during the study by use ofDoppler scanning.
Assays
Glucose. Plasma glucose concentrations were measured by the glucose oxidase method
using a Beckman glucose analyser (Beckman, Palo Alto, CA).
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Insulin. Plasma insulin concentrations were measured in duplicate by two-site
immunospecific insulin ELISA, as previously described (11,17). In brief, the assay uses two
monoclonal murine antibodies (Novo Nordisk, Bagsvaerd, Denmark) specific for human
insulin. The detection range of this insulin ELISA was 5-600 pmol/1. At medium (150
pmol/1), medium-high (200 pmol/1) and high (350 pmol/1) plasma insulin concentrations, the
interassay coefficients of variation were 3.7%, 4.0%, 4.5% and the corresponding intra-
assay variations were 2.3%, 2.1%, 2.0%. There was no cross-reactivity with proinsulin and
split 32,33 and des 31,32 proinsulins, respectively.
C-peptide. Plasma C-peptide concentration was assayed with a commercially available kit
(K6218; DAKO, Cambridgeshire, UK). The assay is a two-site ELISA based on two
monoclonal antibodies, using the same principles referred to above. Each sample was
assayed in duplicate; intra- and inter-assay variation coefficients were 2.2% and 3.3%
respectively.
Data analysis
Detection and quantification ofpulsatile insulin secretion by deconvolution anaylsis.
The plasma insulin concentration time series were analysed by deconvolution as previously
validated (18) to detect and quantify insulin secretory bursts (6). Deconvolution of plasma
insulin concentration data was performed with a multiparameter technique that requires the
following assumptions. Plasma insulin concentrations measured in samples collected at 1-
min intervals were assumed to result from five determinable and correlated parameters: 1) a
finite number of discrete insulin secretory bursts occurring at either regular or randomly
dispersed times and having a) individual amplitudes (maximal rate of secretion attained
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within a burst) and mass (integral of the calculated secretory event) and b) a common half-
duration (duration of an algebraically Gaussian secretory pulse at half-maximal amplitude),
which are superimposed on c) a basal time-invariant insulin secretory rate; 2) a bi-
exponential insulin disappearance model in the systemic circulation, consisting of earlier
directly estimated half-lives of 2.8 and 5.0 min and a fractional slow component of 0.28 in
healthy fasting humans; 3) a bi-exponential insulin disappearance model in portal
circulation, consisting of half-lives of 1.0 and 3.0 min and a fraction slow component of
0.667. These parameters achieved the statistically best fit (maximally reduced fitted
variance) of the portal vein insulin concentration profile. All secretory rates were expressed
as mass units of insulin (picomoles) released per unit distribution volume (liters) per unit
time (minutes).
Statistical analysis
Data are presented as the mean ± SEM. Statistical comparison between groups was made by
Student's two-tailed t-test. In order to examine the relationship between insulin
concentration fluctuations observed in the portal vein and systemic circulation, cross
correlation was performed. Cross correlation analysis relates each portal vein insulin
concentration to a corresponding value in the matching arterial series. This procedure
consists of linear correlations carried out repeatedly at various time lags between the paired
concentrations. Thus, at zero time lag, each portal vein plasma insulin concentration is
compared with a time delayed measure (e.g. lag time minus 2 minutes) in the systemic
circulation sample. By this means, one collects an array of correlations that depend on the
time matching of the two series.
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In order to examine the relationship between pulses identified in the portal vein and
systemic circulation we also performed peak concordance on these pulses from both sites.
Peak concordance is a statistically independent (from cross correlation) method to establish
the relationship between detected pulses in two sampling sites. After identifying discrete
insulin secretory bursts in the two time series (portal and peripheral) exact coincidence was
defined by simultaneous pulse concordance (i.e. peak maxima occurred within one-half
sampling interval of each other). Lagged coincidence was defined accordingly (e.g. with
portal (+lags) or peripheral (-lags) peaks occurring first. The hypergeometric probability
density (joint binomial distribution) was used to estimate the expected number of randomly
concordant pulses, and the probability of falsely refuting the null hypothesis of pure chance
concordance of the observed coincidences.
Results
Mean plasma glucose, insulin and C-peptide concentrations (figure 1)
The mean arterialized plasma glucose concentrations during the basal (fasting) and
stimulated (hyperglycemic clamp) sampling periods were 5.3±0.3 and 8.1±0.1 mmol/1
respectively (p<0.001). As expected, there was a rise in the mean arterialized (basal vs
stimulated, 209±7.4 vs 456±16.8 pmol/1, pO.OOl) and mean portal vein (basal vs
stimulated, 440±25.3 vs 1020.7±72.3 pmol/1, p<0.001) insulin concentration following the
increase in the plasma glucose concentration from 5.3 to 8 mmol/1 during the hyperglycemic
clamp. The mean arterialized C-peptide concentration also increased with hyperglycemia
(basal vs stimulated, 1.8±0.1 vs 2.7±0.1 nmol/1, pO.OOl) confirming an increase in insulin
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Mean arterialised plasma glucose (top panel), C-peptide (middle panel)
and both arterialised (open squares) and portal vein (solid squares)
insulin concentrations. T=0-40 min corresponds to the basal intensive
sampling period. The hyperglycaemic clamp was initiated at t=40 min
and steady state hyperglycaemia was achieved by t=80 mins when the
second intensive sampling period was undertaken.
portal vein insulin concentration was higher than the corresponding arterialized insulin
concentration in both basal (p<0.001) and stimulated (p<0.001) sampling periods (figure 1).
Portal vein blood flow
The mean portal vein blood flow was in the 2 cases in which it was measured 1.1 L/min and
0.8 L/min. There was no change in the portal vein blood flow between the basal state and
the hyperglycemic clamp.
Insulin concentration profile (figure 2, 3)
Inspection of the plasma insulin concentration profiles from the individual patients
indicated the presence of recurrent oscillations in both arterial and portal circulation in all
patients. The magnitude of these oscillations was much larger in the portal circulation
(figure 2) in both the basal and stimulated states compared with the corresponding profiles
from the systemic circulation. The amplitude of the oscillations increased during
hyperglycemia (figure 2). The range of the insulin pulse amplitude observed in the portal
circulation was 100-1000 pmol/1 in the basal state and increased to 200-3000 pmol/1 during
the hyperglycemic clamp. This contrasts with the corresponding range of pulse amplitudes
observed in the systemic circulation of 10-30 pmol/1 and 40-100 pmol/1 in the basal and
stimulated states respectively (figure 3).
Pulse detection
When the insulin concentration profiles were subjected to deconvolution, insulin pulses
were invariably identified in both the portal and systemic circulation (figures 4a,4b,5a,5b).

































Plasma insulin concentration profiles from the basal (t=040
min) and hyperglycaemic clamp (t=80-120 min) period in 2
cases obtained from the arterialised (open squares) and portal
vein (solid squares) sampling sites. The scales are adjusted in
the left and right panels to accommodate the insulin
concentration range observed. Oscillations in insulin





Plasma insulin concentration profile observed from the arterialised
sampling catheter in case 2 in the basal state (t=0-40 min) and during
hyperglycaemia (t=80-120 min). The scale has been adjusted for
each sampling period to maximise the visualization of oscillations.
In comparison, with the arterialised insulin concentration profiles in
figure 2, the expanded scale clearly illustrates the prominent
oscillations in insulin concentration in both basal and stimulated
state.











































The portal vein insulin concentration profile and corresponding
deconvolved insulin secretion rates obtained the intensive
sampling periods in the basal state and during hyperglycaemic


























The arterialised insulin concentration profile and corresponding
deconvolved insulin secretion rates obtained during the
intensive sampling periods in the basal and during
hyperglycaemic clamp periods for case 1.









































The portal vein concentration profile and corresponding
insulin secretion rates obtained during the intensive sampling
periods in the basal state and during hyperglycaemic clamp





































The arterialised insulin concentration profile and
corresponding deconvolved insulin secretion rates obtained
during the intensive sampling periods in the basal and during
the hyperglycaemic clamp periods for case 2.
418±155 vs 1078+368 pmol/1, p<0.05) and systemic (basal vs stimulated, 75+10 vs 241+61
pmol/1, p<0.05) circulation (figure 6). Furthermore, the measured pulse mass/volume of
distribution was ~5-fold larger in the portal circulation in both basal and stimulated states.
The pulse amplitude determined by deconvolution was also markedly (7-8 fold) larger in
the portal circulation in both basal (portal vs systemic, 254+158 vs 23+2.7 pmol/l/min) and
stimulated (portal vs systemic, 524+337 vs 72+19.8 pmol/l/min) states confirming the
impression gained by inspection of the insulin concentration profiles. The corresponding
four pulse half-duration estimates were similar, with a global mean of 2.9 min. The inter-
pulse interval (figure 6) determined by direct portal vein sampling was similar in both the
basal sampling period as well as during the clamp (figure 6). The pulse interval detected by
sampling from the systemic circulation was slightly but not significantly higher than that
observed in the portal circulation.
In the portal circulation, the calculated proportion of insulin derived from discrete insulin
secretory bursts was 64+1.6% in the basal state and 93+2.9% during the hyperglycemic
clamp. In contrast, in sampling from the systemic circulation, the calculated proportion of
insulin secreted in the pulsatile mode was apparently lower than from the simultaneous
sample measurements obtained from the portal circulation (basal state; portal vs systemic,
66+1.8 vs 35+4.1%, p<0.05) and stimulated (portal vs systemic, 93+2.9 vs 56+1.2%,
p<0.01). Both autocorrelation and peak concordant analysis independently revealed a




















The mean insulin inter-pulse interval (top panel), pulse mass
(middle panel) and pulse amplitude (bottom panel) during the
basal sampling period and the stimulated hyperglycaemic
period evaluated by sampling from the portal vein (open panels)
versus the arterial catheter (shaded panels). Units are min (pulse
interval), pmol/L (mass) and pmol/L/min (amplitude)
1
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Figure 7. Cross-correlation analysis of arterial and portal vein insulin
concentration data in the basal and stimulated state. These data
illustrate that changes in serial portal vein insulin concentrations
precede those in the systemic circulation by 1 to 3 minutes
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Discussion
The present study uses direct and high-frequency sampling from the portal vein to affirm
that insulin is secreted in humans almost exclusively in discrete secretory bursts, and that
hyperglycaemia enhances insulin secretion by selective amplification of the mass of insulin
contained within each secretory burst. Furthermore, we could establish that the pre-hepatic
frequency of insulin pulses is ~5 minutes, which in fact corresponds with that observed in
the portal vein of dogs in vivo (5,6), and from isolated perfused islets in vitro (14,15).
There has been some disagreement in the literature as to the frequency of pulsatile insulin
secretion in vivo with estimates ranging from ~6 (5,6) to ~20 (2,3,4,7,8) minutes. When we
measured pulsatile insulin release directly from the canine portal vein, the interpulse
interval averaged 6 minutes, based on a conventional insulin immunoassay and a
deconvolution program specifically validated for insulin pulse detection (5,6). Although
this pulse frequency corresponded to that observed in perfusion of single islets in vitro, it
was three times greater than that observed previously in humans by sampling from the
systemic circulation (2-4,7,8). We postulated that the reason for this large discrepancy was
the relative loss of insulin signal when insulin pulses are examined in the systemic
compared with the portal circulation (6).
At least in the canine model, we confirmed that the sampling site was crucial when a
conventional insulin assay was employed (5), since simultaneous estimates in the portal
vein and the systemic circulation revealed an insulin interpulse interval of 6.7 minutes and 9
minutes, respectively (5). The insulin pulse detection was further obscured by using a 2-
minutely sampling regime in the systemic circulation, as employed in some earlier reports
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(7). The disadvantages of sampling from the systemic circulation were especially evident
when the only available insulin assays were conventional immunoassays (20). Even
multiple replicates by these assays, which have cross reactivity with proinsulin and insulin
split products, do not allow for fully reliable detection of high frequency insulin pulses in
the systemic circulation. However, the introduction of the more sensitive and specific
ELISA assays for insulin (17) should theoretically overcome some of these problems.
Recently, using an ELISA for insulin measurements, we reported an insulin pulse frequency
of -8 minutes when sampling in the systemic circulation in humans (11,12). The present
study now confirms directly that the systemic sampling route can provide an accurate
estimate of insulin pulse frequency in vivo in humans when the insulin concentration is
measured by a sensitive and specific ELISA method and submitted to appropriate
deconvolution-based analysis.
Sampling directly from the portal circulation revealed a remarkable magnitude of insulin
oscillations at this site. In the present study, the amplitude of insulin concentrations in the
portal vein were -100-1000 pmol/1 in the basal state and increased to -500-5000 pmol/1
during hyperglycemia. These values in the human are comparable with those observed in
the canine portal vein (5,6) and presumably reflect the insulin concentration wavefront to
which the liver is exposed. Although the present study subjects were necessarily only those
with portal hypertension requiring treatment, we selected subjects with normal or near
normal liver function tests who were clinically well and had normal pre-study OGTT's.
Moreover, the range of insulin oscillations observed in the portal vein in these subjects is
comparable with that previously observed in healthy dogs (5,6) and the portal vein blood
flow, when available, was in the normal reported range for humans. Although some studies
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have reported that pulsatile insulin delivery (to the peripheral circulation) enhances insulin
sensitivity, none has yet recapitulated the magnitude of insulin oscillations to which we
observe the liver is exposed in vivo during stimulated enhanced insulin secretion (21,22).
The question remains, therefore, what the physiologic importance is, if any, of exposing the
liver to such dramatic oscillations of insulin concentration. Since the magnitude of
peripheral insulin pulses is decreased in patients with Type 2 diabetes (23), it is likely that
the liver in these patients is exposed to even more attenuated oscillations in insulin pulse
amplitude which may contribute to the hepatic insulin resistance characteristic of this
disease (24).
The remarkable transhepatic attenuation of the insulin pulse signal from the portal
circulation to the systemic circulation observed here is comparable to that observed
previously in the dog (5). Although the attenuation may reflect up to ~4-fold dilution of
portal venous blood by the systemic venous drainage, the insulin pulse amplitude is damped
to a much greater extent than this (~10 fold). Presumably the latter reflects hepatic insulin
clearance of insulin pulses. We previously noted that the hepatic clearance of portal vein
insulin in the dog is related in an ascending monotonic (quadratic) manner to the pulse
amplitude of the insulin concentration wavefront presented to the liver (25). Thus, we
speculated that there is preferential hepatic clearance of the pulsatile component of insulin
delivery. This notion is supported by our observation in the current study that there is a
marked drop in the proportion of post-hepatic pulsatile insulin delivery (measured by
arterial sampling) derived versus the pre-hepatic pulsatile insulin secretion (measured in the
portal vein). In one prior study in which blood was sampled from the portal vein of patients
with cirrhosis, comparable, large oscillations in insulin concentration were observed,
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although no quantification of pulsatile insulin release or corresponding arterial sampling
was available (26).
In summary, direct sampling from the portal vein in humans establishes an insulin
interpulse interval of ~5 minutes, and thereby resolves the discrepant insulin pulse
frequency previously reported in humans. A comparable insulin interpulse interval can also
be detected by high-frequency peripheral sampling with the use of a highly sensitive insulin
assay and appropriately validated pulse detection. Direct portal vein sampling also reveals
that in humans the majority of insulin is secreted in insulin bursts, and that apparently
preferential hepatic extraction of pulses leads to post- hepatic delivery of ~50% of insulin in
discrete bursts. Extraction may be even higher in healthy subjects. Finally, we confirm that
the liver in humans, like that of dogs, is exposed to dramatic insulin concentration
oscillations that far exceed the magnitude evaluated to date in clinical studies of insulin
action in vivo.
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Chapter 3
Acute effects of diazoxide on pulsatile insulin secretion in patients with Type
2 diabetes mellitus
Introduction
Type 2 diabetes mellitus is characterised by abnormal insulin secretion. The patterns of
secretory defects include loss of first phase insulin secretion (1), increased irregularity of
insulin release (2,3) and diminished insulin pulses (4).
Glucose-induced insulin release is partly achieved through the generation of ATP molecules
following glucose oxidation and its subsequent interaction with the ATP sensitive
potassium channels on the (3 cell membrane (5-7). This in turn leads to depolarisation of the
P cell membrane, an influx of ionised calcium through the voltage gated calcium channels
• 9+ •
resulting in the elevation of cytoplasmic Ca concentration and exocytosis of the
membrane bound (docked) insulin vesicles. Diazoxide, a potassium channel opener, inhibits
insulin release by preventing the closure of ATP sensitive potassium channels in beta cells
(8). Diazoxide has been shown to partially restore insulin secretion in patients with Type 2
diabetes when administered over one week period (9). It has also been shown to prevent the
development of diabetes in Zucker Fatty rats (10) as well as rats previously subject to 90%
partial pancreatectomy (11). The mechanism of this beneficial effect of diazoxide is not
known. It has been hypothesised that, by "resting P cells", islet insulin stores are preserved
(11). Alternatively, the beneficial effects of diazoxide may be achieved by restoration of the
pattern of insulin secretion. For example, by decreasing the intrinsic excitablility of P cells,
diazoxide may enhance the regularity of insulin release and/or the magnitude of discreet
insulin pulses. This could have secondary beneficial effects by enhancing insulin sensitivity,
and thus, decreasing insulin requirements.
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In the present study we thus sought to test the following hypotheses. During exposure to
diazoxide, insulin secretion in patients with Type 2 diabetes is characterised by (1)
increased regularity, and (2) enhanced pulsatility of insulin secretion. To accomplish this,
we examined the pattern of insulin secretion in patients with diet controlled Type 2 diabetes
during a hyperglycemic clamp (thereby fixing the glucose stimulus for insulin secretion) on
two occasions. On one occasion, following administration of an infusion of diazoxide (in
view of its long half-life remained active during the period of study) and on the other
occasion, in the absence of diazoxide.
Methods
Study subjects and design
Five patients with diet-controlled type 2 diabetes were studied in the Edinburgh University
Wellcome Trust Clinical Research Facility, Western General Hospital, Edinburgh. This
study was approved by Lothian Ethics Committee and all volunteers provided written
informed consent. Inclusion criteria for patients with type 2 diabetes were the fulfilment of
WHO diagnostic criteria for either fasting plasma glucose above 7.8 mmol/1 and/or plasma
glucose above 11.1 mmol/1 2 hours after ingestion of 75 gram carbohydrate, onset of
diabetes after 35 years of age and absence of diabetic ketoacidosis. Exclusion criteria were
pregnancy, abnormal liver or renal function tests, history of pancreatitis, ischaemic heart
disease, cerebrovascular disease, hypotension, uncontrolled hypertension, epilepsy, anaemia
and treatment with sulphonylurea or insulin. The characteristics of all the study subjects are
listed in Table 1.
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TABLE 1
Characteristics of study subjects (mean ± SE)
Age (yrs) 55.8 ±3.5
Duration of diabetes (yrs) 2.8 ±0.7
Body mass index (m/kg ) 31.0 ± 1.6
HbAlc (%) 7.0 ±0.4
Study protocol
All patients were admitted to the Edinburgh University Wellcome Trust Clinical Research
Facility at 8 am on the study day after an overnight fast. All anti-hypertensive medications
were omitted on the morning of the study. They were studied twice; on one occasion after a
diazoxide infusion and on the other occasion after a saline infusion. The studies were
carried out 2-3 weeks apart. On each occasion, study subjects were placed in the supine
position on a bed and 2 intravenous infusion catheters were inserted. They were placed in an
antecubital vein (one in each arm) for the subsequent infusion of glucose and saline with or
without diazoxide respectively. A third intravenous catheter was placed in a dorsal hand
vein (the hand being warmed by an electric blanket to 40 °C) for the purpose of sampling
arterialised blood. At protocol time 0 (approximately 9:00 am) blood was obtained at 1-
minute intervals for 40 minutes (t=0-40 min) for subsequent measurement of the plasma
insulin concentration. Additional samples were obtained at 20-minute intervals for
measurement of the plasma C-peptide concentration as well as 5-minute intervals for
measurement of the plasma glucose concentration throughout the study. At t=40 min, a
glucose infusion was commenced to initiate a hyperglycaemic glucose clamp with a target
plasma glucose concentration of 9-10 mmol/1. This was achieved by a variable rate infusion
of exogenous glucose (50% dextrose) varied in response to the results of the five-minutely
plasma glucose concentrations. The hyperglycaemic clamp was maintained throughout the
remainder of the study (t=40-410 min). During protocol period t=80-l 10 min, diazoxide
was infused at 2 mg/kg/min. 4-5 hours after the diazoxide infusion, a second intensive 40
minute intensive (minutely) sampling protocol was undertaken (again to obtain plasma for
subsequent insulin assay).
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Throughout the study, the blood pressure and pulse rate were monitored at 15-30 min
intervals by an automated BP monitor (Dynamac). Blood samples for subsequent insulin
and C-peptide assay were collected into chilled EDTA tubes, centrifuged and the plasma
stored at -20 °C for subsequent assay. Following this second intensive sampling period the
study was completed (at approximately 4 p.m.) and patients ingested a meal prior to leaving
the Edinburgh University Wellcome Trust Clinical Research Facility.
Assays
Glucose. Plasma glucose concentrations were measured by the glucose oxidase method by a
Beckman glucose analyser (Beckman, Palo Alto, CA).
Insulin. Serum insulin concentrations were measured in duplicate by a two-site
immunospecific insulin ELISA as previously described. In brief, the assay uses two
monoclonal murine antibodies (Novo Nordisk, Bagsvaerd, Denmark) specific for insulin.
The detection range of this insulin ELISA was 5-600 pmol/1. At medium (150 pmol/1),
medium-high (200 pmol/1) and high (350 pmol/1) plasma insulin concentrations, the
interassay coefficient of variation were 3.7%, 4.0% and 4.5% respectively and the
corresponding intra-assay variations were 2.3%, 2.1% and 2.0% respectively. There was no
cross-reactivity with proinsulin and split 32,33 and des 31,32 proinsulins, respectively.
C-peptide. Plasma C-peptide concentrations were performed using a commercially available
kit (K6218; DAKO, Cambridgeshire, UK). The assay is a two-site ELISA based on two
monoclonal antibodies. Each sample was assayed in duplicate; intra- and inter-assay
variation coefficients were 2.2% and 3.3% respectively.
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Data analysis
Detection and quantification ofpulsatile insulin secretion by deconvolution.
The plasma insulin concentration time series were analysed by deconvolution to detect and
quantify insulin secretory bursts. Deconvolution of venous insulin concentration data was
performed with a multiparameter technique (12) that requires the following assumptions.
Plasma insulin concentrations measured in samples collected at 1-min intervals were
assumed to result from five determinable and correlated parameters: 1) a finite number of
discrete insulin secretory bursts occurring at either regular or randomly dispersed times and
having a) individual amplitudes (maximal rate of secretion attained within a burst) and mass
(integral of the calculated secretory event) and b) a common half-duration (duration of an
algebraically Gaussian secretory pulse at half-maximal amplitude) that are superimposed on
c) a basal time-invariant insulin secretory rate; and 2) a bi-exponential insulin disappearance
model in the systemic circulation, consisting of earlier directly estimated half-lives of 2.8
and 5.0 min and a fraction slow component of 0.28 in healthy fasting humans (13). All
secretory rates were expressed as mass units of insulin (picomoles) released per unit
distribution volume (litres) per unit time (minutes), where the volume of distribution was
0.206 1/kg. Total insulin secretion was calculated by deconvolution of C-peptide
concentrations (14).
Total body insulin clearance was estimated from the calculated pre-hepatic insulin secretion
rates (from deconvolution of C-peptide concentrations) and from peripheral plasma insulin
concentrations.
C (L/min) = S (pmol/min)/I (pmol/L)
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where C is the net insulin clearance rate, S is calculated insulin secretion rate and I is the
peripheral plasma insulin concentration.
Quantification of irregularity.
The orderliness of insulin secretion was assessed by the application of approximate entropy,
which is a model-independent and scale-invariant statistic (15). Approximate entropy
assigns a single non-negative real number to a time series in which larger absolute values
correspond to greater apparent process randomness, and smaller values correspond to more
instances of recognizable patterns or consistent features in the data. Briefly, approximate
entropy measures the logarithmic likelihood that runs of patterns that are close (within r) for
m contiguous observations remain close (within the same tolerance width r) on next
incremental comparisons. For this study, we calculated approximate entropy values for all
data sets, with m= 1 and r=20% of the SD of the individual subject time series. We applied
approximate entropy with these input parameters to the first-differenced serum insulin
concentration time series to minimize the effects of short-term nonstationaries in the data.
Statistical analysis
Data are presented as the mean ± SEM. Statistical comparison between groups was analysed
either by a paired Student's two-tailed t-test (comparisons between diazoxide versus saline
study at fixed times) or one factor analysis of variance (comparisons over time in one or
other group). A probability of less than 5% due to occurrence of chance alone (p<0.05) was




Bloodpressure andplasma glucose concentration.
The mean plasma glucose concentration prior to the clamp (during the basal intensive
sampling period) was comparable on the two study occasions (saline vs diazoxide, 8.310.9
vs 8.311.1 mmol/1). During the hyperglycemic clamp the plasma glucose concentration was
successfully maintained in the target range and was again comparable on the two study days
(saline vs diazoxide, 9.4 1 0.8 vs 9.7 1 0.9 mmol/1) (figure 1).
There was no difference in the mean systolic blood pressure during the basal study period
(t=0-40 min) (saline vs diazoxide, 129.713.1 vs 135.6+1.7 mm Hg, p=0.14 ANOVA). The
mean systolic blood pressure decreased during and following diazoxide infusion (saline vs
diazoxide, 131.511 vs 121.411.2 mm Hg, p<0.001 ANOVA), an effect which persisted until
the end of the study (figure 2).
Diazoxide effects on insulin and C-peptide concentrations.
The mean basal plasma C-peptide concentrations prior to the diazoxide or saline infusions
was similar (diazoxide vs saline, 1.1710.12 vs 1.1610.13 nmol/1, p=0.65). During the
hyperglycemic clamp there was an expected increase in the C-peptide concentration on the
saline study day (from 1.1610.13 to 1.60+0.3 nmol/1, basal versus final hour of clamp,
p<0.01). However, during the clamp, following the initiation of the diazoxide infusion until
the end of the study, the C-peptide concentrations were lower compared to the




Fig 1. Plasma glucose concentration throughout study.
Systolic BP
lime (irin)
Fig 2. Mean systolic blood pressure throughout study.
diazoxide vs saline, 1.09±0.18 vs 1.47±0.24 nmol/1, p<0.01; five hours after diazoxide,
diazoxide vs saline, 1.4±0.3 vs 1.6±0.3 nmol/1, p<0.05). This relatively steady state
suppression of insulin secretion for the five hours after diazoxide indicated by the decreased
C-peptide concentration is consistent with the prolonged biological half life of diazoxide
(28 hours) (figure 3).
As expected the mean plasma insulin concentration was comparable in the basal state prior
to the clamp on both the diazoxide and saline visits (diazoxide vs saline, 90.7±15.7 vs
77.4±13.3 pmol/1, p=0.1). However, in contrast to the C-peptide concentrations, during the
final hour of the clamp the mean plasma insulin concentration after the diazoxide and saline
infusions were comparable (diazoxide vs saline, 140±60 vs 134.7±49 pmol/1, p=0.6) (figure
4). As the C-peptide and insulin concentrations were stable at this time these data imply that
diazoxide caused a decrease in insulin secretion but no change in insulin concentration in
the systemic circulation.
Diazoxide effects on pulsatile insulin secretion
Inspection of the individual insulin concentration profiles in each patient confirmed the
presence of oscillations in insulin concentration with a pulse interval of approximately 6
minutes. When these insulin concentration profiles were subject to analysis with a
deconvolution program previously validated for this purpose, pulses were indeed detected in
each data set analyzed.
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Fig 4. Mean plasma insulin concentration during final hour of
hyperglycaemic clamp.
In the basal fasting state, there was no difference in the calculated mean insulin secretory
rate (diazoxide vs saline, 3.3±0.2 vs 3.3±0.3 pmol/kg/min, p=0.7), pulse mass (diazoxide vs
saline, 48.3+10.3 vs 30.8+8.6 pmol, p=0.2), pulse interval (5.5+0.2 vs 5.4+0.2 mins, p=0.8)
and pulse amplitude (diazoxide vs saline, 13.9+2.9 vs 9.4+1.6, pmol/1, p=0.14) consistent
with the comparable C-peptide concentrations under these conditions. However, following
diazoxide infusion, during the clamped period of the second intensive sampling period, the
insulin secretion rate was decreased (diazoxide vs saline, 4.2 ±0.7 vs 4.8+0.6 pmol/kg/min,
p<0.05) consistent with the observed reduction in C-peptide level. However, the pulse mass
(diazoxide vs saline, 47.0+17.7 vs 43.7+9 pmol, p=0.7), pulse interval (diazoxide vs saline,
5.9+0.5 vs 5.0+0.3 mins, p=0.05) and pulse amplitude (diazoxide vs saline, 13.4+6.4 vs
16.1+3.5 pmol/1, p=0.4) were not different from the corresponding data obtained after the
saline infusion. Interestingly, insulin clearance was significantly decreased following
diazoxide infusion (diazoxide vs saline, 3.5+0.7 vs 3.9+0.9 L/min, p<0.01).
Effects ofdiazoxide on the orderliness of insulin concentration profiles.
The orderliness of insulin concentrations were not changed after diazoxide (diazoxide vs
saline, 1.1+0.05 vs 1.1+0.03, p=0.9).
Discussion
The present study was undertaken in order to test the hypothesis that in patients with Type 2
diabetes, diazoxide results in enhanced pulsatile and/or orderliness of insulin secretion. We
conclude that, while diazoxide did cause an expected decrease in the rate of pre-hepatic
insulin secretion, unexpectedly under these conditions neither the rate of post hepatic
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insulin delivery or post hepatic insulin pulse mass (or amplitude) was altered. No changes in
orderliness of insulin secretion were seen under these conditions.
The apparent disparity between the decreased pre-hepatic insulin secretion rate (C-peptide)
but comparable post-hepatic insulin secretion rates during exposure to diazoxide may have
several explanations. One possible explanation is that the clearance rate of C-peptide and/or
insulin may theoretically be altered by diazoxide. However, there is no data to support this.
An alternative explanation is that the hepatic clearance rate of insulin is decreased in the
presence of diazoxide. We have previously reported unchanged insulin concentrations in
the systemic circulation during partial suppression of insulin secretion (measured directly in
the portal circulation in a canine model) during a low dose somatostatin infusion (16). In
those studies, as we had direct access to the portal circulation, we were able to reveal that
there was a strong relationship between the pulse amplitude of the portal vein insulin
concentration and hepatic insulin clearance rate. It has long been recognised that the
concentration of insulin in the systemic circulation depends on both the rate of insulin
secretion and the hepatic insulin clearance rate. Since virtually all insulin is secreted in
discrete insulin bursts (13,17), we previously proposed that the decreased rate of hepatic
insulin clearance of endogenously secreted insulin may serve as an adaptive mechanism to
sustain the concentration of insulin in the systemic circulation under conditions of
diminishing secretion rates (for example during evolving Type 1 or Type 2 diabetes
mellitus) (16). More recently we have identified additional support for this concept in a
porcine model of partial P cell loss achieved with alloxan (18). In these animals we again
observe that insulin concentrations in the systemic circulation are preserved in the setting of
decreased insulin secretion rates and that this disparity is due to decreased hepatic insulin
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clearance rates of endogenously secreted insulin. In that porcine model with the benefit of
portal vein catheterisation we again observed a direct relationship between the insulin pulse
amplitude and the rate of clearance of endogenously secreted insulin, namely, that smaller
pulses were associated with reduced clearance. Therefore, it is plausible that the
discrepancy between the C-peptide and insulin concentration data observed in this study is
due to diazoxide-induced decrease in pre-hepatic insulin secretion leading to smaller pulse
amplitude in the portal vein insulin concentration resulting in a compensatory decrease in
hepatic insulin clearance of endogenously secreted insulin. Such a circumstance might be
deemed beneficial under conditions of impaired (3 cell function as comparable insulin
concentrations are achieved in the systemic insulin concentrations despite a decreased rate
of insulin secretion.
It is known that insulin secretion is irregular and chaotic in patients with Type 2 diabetes
(2). The statistic approximate entropy has been used to document increased disorderliness
of insulin concentration profiles (19). We hypothesized that diazoxide might decrease the
disorderliness of insulin concentration profiles by reducing the excitability of P cell
membranes by retaining the potassium channels open (and so increasing resting membrane
potential). However under the conditions of the present study there was no effect of
diazoxide on orderliness of insulin concentrations.
It is of related interest that diazoxide treatment had no effect on the insulin pulse interval.
Therefore, the rhythmic activity of pancreatic pacemaker is not influenced by diazoxide.
The pacemaker responsible for the generation of insulin pulses remains controversial.
Various hypotheses have been proposed for the origin of pancreatic pacemaker, namely,
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oscillations in glycolysis (metabolic) (20), cytoplasmic Ca2+ (21) concentration or intra-
pancreatic ganglia (22). Since oscillations in insulin concentration were observed despite
under the inhibitory influence of diazoxide, the metabolic origin as the pancreatic
pacemaker is more likely although the contribution of intra-pancreatic ganglia cannot be
ruled out. This is consistent with in vitro studies demonstrating the occurrence of oscillatory
insulin secretion from pancreatic islets exposed to diazoxide where the membrane potential
has been 'clamped' by diazoxide (23).
In summary, we report that peripheral insulin concentrations did not decrease despite
reduction in pre-hepatic insulin secretion following diazoxide infusion. This could be
ascribed to the reduction in hepatic insulin clearance following the reduction in insulin
pulse amplitude in the portal circulation. Finally, inter-pulse interval remained unchanged
after diazoxide implying that the pancreatic pacemaker activity is a stable phenomenon.
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Chapter 4
Pulsatile insulin secretion by human pancreatic islets
Introduction
Insulin is secreted in a pulsatile manner (5,10,11,14,22). These pulses can detected in vivo
as well as in vitro in perifused islets of Langerhans (2,3,5,6,8,9,15). Reliable detection and
quantification of pulsatile hormone secretion requires statistical methods that have been
validated for the conditions in which they will be used. We have previously validated the
use of a deconvolution technique developed by Johnson and Veldhuis (29) for detection and
quantification of pulsatile insulin secretion in vivo (22). In the present study, we sought to
extend this approach for the quantification of pulsatile insulin secretion by perifused human
islets of Langerhans. Perifiision studies have the advantage that they allow analysis of the
mechanisms that regulate insulin secretion in the absence of the complexities of feedback
control (for example by the changes in plasma glucose concentration). They also allow
mechanistic studies into the factors that generate pulsatile insulin secretion (pacemaker
activity) as well as coordinate this signal between islets (coordination).
In the present study, we appraised the sensitivity and specificity of two statistically
independent methods for pulse detection, Cluster analysis (31) and deconvolution analysis
(7). Optimized pulse detection was then applied to examine pulsatile insulin secretion in
response to relevant stimuli (glucose and potassium) to explore the mechanism(s) driving
enhanced insulin release.
Methods and materials
Protocol 1: Sensitivity and specificity of pulse detection
The purpose of this protocol was to establish the criteria for valid insulin pulse detection
from perifused human islets. Fluctuations in insulin concentration in perfusate collected
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from perifused islet include contributions from assay variance, experimental variability, and
genuine oscillations in the insulin secretion rate. Therefore the influence of each of these
components on two published methods for detection of pulsatile insulin secretion, Cluster
analysis and deconvolution, were examined in protocol la, lb and lc. The objective was to
minimize detection of pulses from system or assay noise (false positive detection), while
maximizing true-positive detection of insulin pulses. To this end, 3 experimental protocols
were performed in which the variance of each component outlined above was examined
within the insulin concentration range (5-100 pmol/1), which corresponds to those observed
in the perfusate from human islets.
Protocol la: Specificity; assay variance.
Human insulin (Actrapid, Novo Nordisk, Bagsvaerd, Denmark) was diluted to five
concentrations (5, 20, 30, 60 and 100 pmol/1) in Krebs' ringer bicarbonate buffer (115
mmol/L NaCl, 4.7 mmol/L KC1, 2.5 mmol/L CaCh, 1.2 mmol/L MgCh, 5 mmol/L NaOH)
supplemented with 0.2% human serum albumin. Forty aliquots were collected from each of
the five insulin concentrations and stored at -20 °C until assayed in duplicate.
Protocol lb: Specificity; system variance.
To determine variance in insulin concentration levels attributable to the perifusion system
the 5 insulin dilutions prepared in la were pumped through the perfusion system (duplicate
experiments) in an identical manner to that in which islets were perfused. Specifically, the
perfusate was gassed with O2/CO2 (95:5) and maintained at pH 7.4 before being pumped
through the system at constant flow rate of 0.3 ml/min for 42 minutes. The effluent was
collected at 1-minute intervals and then stored at -20 °C prior to assay.
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Protocol lc: Sensitivity oftrue pulse detection.
We simulated oscillations of insulin concentration (in a range comparable to those observed
from human islets) in the effluent from the perifusion system by superimposing four
amplitudes of insulin oscillation (7.5, 12.5, 22.5 and 50 pmol/1) onto each of the 5 constant
insulin infusions (total of 20 perfusions) described in lb. In each experiment 7 pulses were
infused over a period of 42 minutes. Pulses were generated in a square wave form for 0.5
minute superimposed on the constant insulin infusion. After the 0.5 minute pulse there was
a 5.5 minute period with the constant basal insulin infusion only, so achieving an inter-
pulse interval of 6 minutes to mimic that observed in human islets. Perfusate effluent was
collected at 1-minute intervals for 42 minutes and stored at -20 °C until assay in duplicate
for insulin.
Apparatus.
The perifusion system consisted of two separate pumps, Endotronic Automated Pumping
System (APS) and ACUSYST-S pumps (Cellex Biosciences, Inc, Minneapolis), linked
together via an integration chamber. The Endotronics APS is a fluid handling system
providing a wide range of capabilities ranging from fixed pump rates to sophisticated signal
control including delivery of a pulsatile infusion pattern. It consists of a control panel and 3
peristaltic pumps (medium, substrate and waste). It has the ability to control the 3 pumps
independently (i.e. to produce a constant rate of infusion) or use a coordinated control
scheme (i.e. to produce pulsatile pattern of delivery) and this capability is achieved through
ACUSOFT-APS software package in an on line personal computer. The ACUSYST-S
perifusion system consists of a multi-channel peristaltic pump, tubing sets, a heat exchanger
and perifusion chambers. The peristaltic pump draws the perfusate from the integration
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chamber and delivers it through the tubing sets. The perfusate is carried through the heat
exchanger where it is warmed. From the heat exchanger, the perfusate is delivered to the
islet chambers. Output from the islet chambers is collected in a fraction collector for
analysis. The infusion rates in the Endotronics APS and ACUSYST-S pumps were
coordinated via ACUSOFT-APS software to achieve a flow rate of 0.3 ml/min and generate
the pulsatile pattern of insulin delivery. The medium and the substance pumps delivered
perfusate of different insulin concentrations to the integration chamber, where it was mixed
prior to delivery to the perifusion system to achieve the desired pulse waveform. Effluent
was collected at one-minute intervals.
Protocol 2: Recovery of infused insulin pulses
The purpose of protocol 2 was to define the dynamics of islet secretion, based on the
observed fluctuations of insulin concentration in the perifusate. The insulin output from the
perifusion system is a function of both the actual secretion dynamics of the islet in the islet
chamber and the damping of this signal in the subsequent drainage system as well as any
losses of insulin via adsorption to the apparatus. Accordingly, we first delivered insulin
pulses directly into the islet chamber in a profile that mimicked the secretory behavior of
islet beta cells predicted by electrophysiology studies (2,12,26). We then used the resulting
profile of insulin concentration data observed in the perifusion effluent to derive the
parameters required to recover the known insulin secretion profile (delivered into the islet
chamber) by use of deconvolution.
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Apparatus.
The ACUSYST-S pump was used to maintain the perfusate at a flow rate of 0.3 ml/min. A
high precision programmable infusion pump (Harvard pumps, Cambridge, MA) was used
to deliver insulin (1000 pmol/1) at the rate of 0.1 ml/min for 2 min every 6 min for insulin
pulse generation.
The Harvard pump was connected to the perifusion chamber directly via an infusion line, so
that the insulin was pumped directly into the chamber. During the time the Harvard pump
was active, the flow rate pumped by ACUSYST-S pump was reduced to 0.2 ml/min in
order to preserve an overall flow rate of 0.3 ml/min.
Protocol 3: Pulsatile insulin release by human islets
In order to examine the pattern of insulin secretion from human islets in the above
perfusion system, we studied single humans islets exposed to basal (5.5 mmol/1) and
stimulated (8, 16 and 24 mmol/1) glucose concentrations (n=4). Single islets were also
studied at basal (5 mmol/1) and high (30 mmol/1) potassium concentrations at a constant
glucose concentration of 5 mmol/1. Since many islet perifusion protocols involve groups of
islets we also examined groups of 5-20 human islets per chamber perifused at 20 mmol/1
glucose (n-20).
Islet isolation.
Human islets were isolated from pancreas tissue retrieved from 4 heart-beating organ
donors by the department of surgery at the University of Leicester, U.K. The donor did not
have a history of diabetes. After isolation, islets were cultured in RPMI 1640 medium
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containing 5.5 mmol/1 glucose, 2 mmol/L glutamine, 10% fetal calf serum, 100 U/ml
benzylpenicillin and 0.1 mg/ml streptomycin. The islets were cultured in Leicester for 2
days before being sent to Edinburgh. Islets were then transferred to fresh RPMI 1640
medium (same composition as above) and cultured for 2 days before experiments were
performed.
Islet perifusion.
Single human islets were removed from the static incubation media, and suspended in Bio-
Gel P-2 beads (Bio-Rad, Hercules, CA) and placed in perifusion chambers. The perifusion
system consisted of a multi-channel peristaltic pump that delivered perfusate through 6
parallel tubing sets via a heat exchanger and six perifusion chambers a rate of 0.3 ml/min
after warming to 37 °C and gassing with 95% O2. The perifusate was delivered to the
perifusion chambers containing the human islets. The perifusion protocol consisted of two
study arms; the islets were exposed to (a) basal glucose (4 mmol/1) concentration for 40 min
and thereafter to 8, 16 or 24 mmol/1 for another 40 min; (b) basal (5 mmol/1) potassium
concentration for 40 min and thereafter, to high (30 mmol/1) potassium concentration for
another 40 min. When the islets were exposed to 30 mmol/1 potassium, the NaCl
concentration was reduced to 96 mmol/1 to keep the osmolarity constant in the Kreb's
Ringer buffer. In each protocol, an equilibrium period of 30 min was allowed before study.
Effluent perifusate was collected at 1-minute interval and stored at -20 °C and subsequently
analyzed for insulin concentration.
82
Assays
Insulin. Insulin concentrations were measured in duplicate by two-site immunospecific
insulin ELISA as previously described (17). The assay uses two monoclonal murine
antibodies (Novo Nordisk, Bagsvaerd, Denmark) specific for insulin. There is no cross-
reactivity with proinsulin and split 32,33 and 31,32 proinsulins. Sensitivity of the assay is 5
pmol/1 and the detection range is 5-2000 pmol/1. The intra-assay and inter-assay CVs
ranged from 2.0-2.3% and 3.7-4.5% respectively. In all the present studies all measured
insulin concentrations were within this operating range of the insulin assay.
Calculations and statistical analysis
Deconvolution analysis calculates underlying insulin secretion rates and the position,
duration, mass and amplitude of insulin secretory bursts as well as the basal or non-pulsatile
insulin secretion rate based on known or assumed half-life parameters (13,29,30). A column
of apparent half-life was estimated by monoexponential fitting of the observed insulin
concentrations in serial one-minute samples following abrupt cessation of a continuous
insulin infusion in two experiments, thereby correcting for secondary skewness imposed on
the perifusion insulin waveform due to non-specific time-delay of column flow-through
(24).
Cluster analysis, in contrast, determines statistically significant up- or down strokes in the
serial insulin concentrations, providing information only about the frequency and amplitude
of the oscillations in the data series without any assumptions or knowledge of the insulin
half-life in the system of study or underlying secretory burst waveform. The t-statistics
used for evaluating significant upstrokes and down strokes in the insulin time series were
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taken as 2.0, based on prior simulation studies. The corresponding estimated cluster sizes
of 2 and 2 in the nadirs and peaks were defined using signal-free insulin profiles (below).
Results
Protocol 1: Sensitivity and specificity for pulse detection
(a) Protocol la: Detection offalse-positive pulses due to assay variance.
Representative insulin concentration profiles obtained in protocol la, lb and lc are shown
in figure 1. Despite the low coefficient of variation of the current insulin assay, fluctuations
in the insulin concentration obtained by multiple replicates from the same sample of buffer
can give the appearance of pulses when plotted sequentially as in figure 1 (top panel).
When using Cluster analysis to examine these data, the criteria required to avoid false
detection of insulin oscillations are shown in table la. Use of a t-score of 2 or greater
resulted in detection of less than 2 false positives for detection insulin oscillations
irrespective of the cluster size selected to define a pulse. As shown below a cluster size of
2x2 was required for reliable detection of true pulses. Thereby, we observe that a mean of
0.8 false positives (never more than 1) was detected in the 6 assay profiles examined. When
the same insulin concentration profiles were subject to pulse detection using deconvolution
(using a single half life of 0.63 min and a volume of distribution of 0.33 ml as established in




































Panel A: 40 assay replicates from the same buffer sample plotted in
sequence of assay; Panel B: insulin concentrations (mean of
duplicates) obtained sequentially from the perfusion apparatus after
perfusion of the same buffer shown in A at a constant rate through
the perfusion apparatus; Panel C: 40 insulin concentrations (mean of
duplicates) obtained in sequence from the perfusion apparatus during
















































































































































































































































































































(b) Protocol lb: Detection ofspurious pulses due to variance in insulin assay and variance
due to the perfusion system.
A representative perifusion insulin concentration profile during constant insulin delivery is
shown in figure 1 (middle panel). The results of Cluster analysis applied to these data are
summarized in table lb. A t-score of 3 or greater irrespective of cluster size detected less
than one pulse with each experiment. A t-score of 1 provided unacceptable rates of false
positives at cluster sizes of 4 by 4 or less. A t-score of 2 revealed false positives pulses at a
rate of less than 2 per 42 minute data series with cluster sizes of 4x4 or greater, and (2-3
false positive errors) at cluster sizes of 2x2 and 3x3. When the same data were subjected to
deconvolution analysis, the rate of false positives averaged 2.5 pulses per 42-minute profile.
(c) Protocol lc: Sensitivity of true-positivepulse detection.
A representative insulin concentration profile obtained during pulsatile insulin perifusion
(seven pulses) is shown in figure 1 (lower panel). Cluster analysis yielded the data
summarized in table lc. A t-score of 3 or greater resulted in a pulse detection rate of less
than 50% in most circumstances. A t-score of 2 allowed detection of 64% of pulses at a
cluster size of 2x2. Although a t-score of 1 and cluster size of lxl detected 99% of pulses,
these criteria led to 6 false-positive pulses over the same period during a constant infusion.
Therefore, the most appropriate Cluster criterion for detection of insulin pulses from human
islets in this perifusion system is a t-score of 2 and cluster size of 2x2. Use of these criteria
provided detection of 64% of true pulses (mean detection rate of all amplitudes infused)
during a pulsatile infusion, while yielding 2.7 false positives on average during a constant
insulin infusion. The design of protocol lc allowed for examination of the impact of the
increment in pulse amplitude above baseline on pulse detection. This analysis under
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optimized Cluster analysis (t=2 and cluster size of 2x2) gave the results shown in figure 2.
When the mean amplitude of the pulse was 40% or greater than baseline, Cluster analysis
detected -80% of pulses. However, when the amplitude of the pulse was only 10-20%
above baseline, Cluster analysis detected -50% of pulses.
When deconvolution was used to examine insulin concentration profiles obtained during
the pulsatile insulin infusions, 94% of true pulses were detected (mean detection rate of all
amplitudes infused). The impact of the amplitude of infused oscillation(s) on pulse
detection is shown in figure 2. Deconvolution detected 85-100% of true pulses when the
amplitude of the insulin pulse above baseline was 20% or more (either 6 or 7 pulses
detected out of 7 true pulses). In conclusion, deconvolution was more sensitive (6% false
negatives versus 34% false negatives with Cluster analysis) and comparably specific (2.5
versus 2.7 false positive per 42 insulin samples during constant infusion) compared to
Cluster analysis.
Protocol 2: Recovery of infused insulin pulses
In this protocol, we tested recovery of insulin secretion kinetics during known pulsatile
insulin infusions given directly into the islet chamber so as to reproduce so closely as
possible the presumed pattern of insulin secretion by human islets. Since deconvolution but
not Cluster analysis measures secretion we employed deconvolution only in protocol 2.
The measured volume of distribution of insulin delivered in this manner to the perifusion
system was 0.33 ml. The decay curve for insulin concentration following cessation of an
insulin pulse fitted conformed to monoexponential decay supporting a single compartment
model with a calculated half-life of 0.63 minutes. Figure 3 allows direct comparison of the
86
Pulse Detection
10-20 20-30 30-40 40-50 50-60 60-70
Anplitude Increase (%)
Fig 2.
Sensitivity of pulse detection by cluster analysis (open bars) and
deconvolution (closed hatched bars) for detecting infused pulses as a
function of the percent increment in amplitude above baseline. 7 pulses
(broken line) were actually infused.
known insulin delivery rates (middle panels), the insulin concentration profile that resulted
from this (top panels) and the calculated insulin secretion rates by use of deconvolution of
these concentration data (lower panels). Deconvolution closely approximated insulin
delivery into the islet chambers. In fact given the inevitable damping of the delivery into a
fluid space, the deconvolution profile is likely more representative of the minute-averaged
appearance of insulin in this chamber than the pumped infusion rate (i.e. Guassian versus
truncated triangles). Furthermore, deconvolution of the insulin concentration profiles
yielded excellent recovery of the known insulin delivery rate (92.4±4.9%) as well as the
known insulin infused pulse mass (94.5±1.6%). The deconvolution program ascertained
that 93+2.5% of insulin delivery was derived from pulses, whereas in this protocol 100% of
insulin was delivered in pulses.
Protocol 3: Pulsatile insulin release by human islets
Pulse detection by deconvolution versus Cluster analysis provided a comparable measure of
pulse interval (6.7+0.5 vs 8.0+1.5 min, p= 0.12; deconvolution vs cluster), when multiple
islets were perfused irrespective of the mean insulin concentration in the islet effluent
(mean insulin concentration 26.1+3.9; range 10.4 to 48.8 pmol/1). Although there is no
known pulse interval with real islets (in contrast to the pseudo islet studies in protocol 2),
the likely pulse interval from electrophysiological studies is ~6 min (7,12,26), and agrees
well with these data. In contrast when single human islets were perifused, the pulse interval
with deconvolution remained comparable to that seen in multiple islet perfusions, whereas
Cluster analysis detected fewer pulses and consequently a longer pulse interval (6.9+1.3 vs





























































value for the pulse interval throughout insulin concentration range observed in the effluent
from single islets (mean 12.2±1.0, range 5.4-22.3 pmol/1). We therefore used only
deconvolution to examine the effects of increased glucose and potassium concentrations on
pulsatile insulin release by single islets.
Recovery of insulin secretion from perifused human islets using deconvolution of the
insulin concentration profile was 102±1.4% for single islets, and 104.8+1.4% for multiple
islets (5-10) (figure 4). The insulin concentration profile in single human islets examined in
the present system invariably revealed distinct oscillations (figure 5). After the perfusate
glucose concentration was increased, the insulin secretion rate per islet increased (2.8+0.2
to 4.9+0.6 fmol/min, p<0.05) and this was achieved by an increase in pulse mass (6.5+2.7
to 19.5+7 fmol, p<0.05) with no change in pulse frequency (8.1+0.9 to 6.3+0.9 min, p=0.1).
Increased perfusate potassium concentration from 5 to 30 mmol/1 also stimulated increased
insulin release (3.9+0.6 to 5.7+0.7 fmol/min, P<0.05), which was analogously achieved
through the specific mechanism of increased pulse mass (6.2+1.4 to 14.5+2.4 fmol, p<0.05)
with no change in pulse frequency (8.1+1.5 vs 8.0+1.7, p=0.9) (figure 6). Based on single
human islets, the calculated proportion of insulin secreted in distinct pulses versus in a
basal (non-pulsatile) insulin release was 25.6+4.7 and 37.2+8.8% (control versus stimulated
with potassium), and 23.3+9.3 vs 56.2+7.2% (basal versus stimulated with glucose). The















Insulin Mass Delivered from Perfusate (fmol)
Fig 4.
The relationship between the insulin mass calculated by the
product of the insulin concentration and the buffer flow rate (X
axes) and the insulin mass obtained by deconvolution (Y axes).
Relationship shown when multiple islets perfused in each











































The insulin concentration profiles (top panels) and the
deconvolved insulin secretion rates (lower panels) in
representative single human islets during basal (t=0-40 min)
and stimulated (t=40-80 min), glucose (4 to 8 mmol/L) and
KC1 (5 to 30 mmol/L). The insulin pulse mass increased in
response to stimulation with high glucose or potassium but
there was no change in pulse frequency.
Fig 6.
The impact of a high potassium concentration on pulsatile secretion
by isolated perfused islets. Pulse mass (left panel), pulse interval
(right panel). Basal potassium 5 mmol/L, stimulated potassium 30
mmol/L. The insulin pulse mass increased in response to
stimulation with high glucose or potassium but there was no change
in pulse frequency.
Discussion
In vivo, most insulin is secreted in discrete secretory bursts (22). Regulation of insulin
secretion is achieved physiologically through the mechanism of modulation of the
amplitude of insulin pulsatility (2,17,23,24,25). Abnormal pulsatile insulin secretion is an
early defect in patients developing Type 1 or Type 2 diabetes (4,17). Accordingly, an
understanding of the mechanisms underlying the generation, co-ordination and regulation
of insulin secretory bursts is potentially of importance. Estimation of pulsatile insulin
secretion in vivo in humans and large animals presents particular experimental and
analytical challenges, including the delivery of insulin into the portal vein and liver,
wherein it undergoes extraction prior to delivery to the usual sampling site, the systemic
circulation (16,18,21). Estimation of pulsatile insulin secretion in rodents is complicated by
the limitations of blood volume. To overcome these problems pulsatile insulin secretion has
frequently been examined in isolated perifused islets (2,3,5,6,9,15). However the
quantification of pulsatile insulin release in isolated islets is not without technical
challenges. The quantity of insulin released by isolated perfused islets is very small and so
such studies are susceptible to the difficulties of distinguishing variability of concentration
data due to noise in the assay system from small fluctuations due to episodic secretion at or
near the limits of the capacity of assay resolution. Furthermore any perfusion system is
vulnerable to experimentally uncontrolled fluctuations in output consistency associated
with mechanical facets of the apparatus.
In the present study, we established the conditions in which pulsatile insulin secretion by
single or multiple perifused human islets can be measured in a (commercially available)
perifusion system using a well-characterized ELISA for human insulin. These
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investigations document optimal criteria for pulse detection from human islets using two
statistically independent methods for pulse detection, cluster analysis and a multi-parameter
deconvolution method. The analyses further define the sensitivity of the two techniques for
pulse detection. The deconvolution technique effectively quantitated insulin secretion rates,
and accurately identified the number, location and magnitude of insulin secretory bursts
exceeding 20% of baseline. Deconvolution provided a similar estimate of the frequency of
insulin pulses whether islets were perifused singly or in groups. Cluster analysis provided a
reasonable estimate of insulin pulse number and location so long as the magnitude of the
oscillations was 40% or more above baseline, and that groups rather than single islets were
studied. Our appraisal highlights a cautionary note inasmuch as multiple assay replicates
per se and/or a perifusion system may generate spurious pulses in insulin concentration
series (protocol la or protocol lb) in the absence of genuine biological secretory bursts. As
the human insulin assay used in the current studies has a lower coefficient of variation and
is more sensitive and specific than available rodent insulin assays or prior human insulin
assays, these problems could be expected to be magnified when studying rodent islets, or
human islets using conventional radioimmunoassays.
Application of the newly validated techniques in human islets (protocol 3) provided some
interesting physiological insights. The frequency of detected insulin pulses from human
islets was one pulse ~7 minutes, which is comparable to that observed in vivo when
sampling directly from the portal vein in dogs or humans (18,21,22). Sampling from the
systemic circulation in humans with conventional immunoassays initially yielded a lower
pulse frequency (e.g. interpulse interval of 15-20 minutes) (4,17). However, subsequent
systemic sampling studies have measured insulin concentration(s) by ELISA and applied
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deconvolution analysis validated for application in vivo (19,24,27). These methods
disclosed insulin pulse frequency comparable to that observed in the current and earlier
studies of single perfused islets. In fact examination of figure 2 reveals how small
amplitude pulses compared to the baseline present in the systemic circulation in vivo are
vulnerable to an underestimate of the pulse frequency, particularly when discrete peak
detection analysis is used. In the current studies, the observed frequency of pulsatile insulin
release by deconvolution was comparable whether islets were perfused as single islets or in
groups of islets. The frequency is consistent with prior studies of perfused groups of islets
(6,12). Using rodent islets, it has been necessary to perifuse groups of islets to allow
adequate detection of insulin release or enlarged single mouse islets from genetically obese
mice (2,3).
The current studies are also consistent with prior in vivo (and in vitro) studies, which
suggest that regulation of the rate of insulin secretion is predominately achieved through
modulation of the pulsatile component of secretion. Here we report that stimulation of
insulin secretion in individual human islets by an increased concentration of glucose or
potassium is achieved mechanistically via the specific enhancement of the insulin pulse
mass with no change in pulse frequency. Measurement of pulsatile insulin in vivo by
sampling from the portal vein to avoid hepatic insulin extraction reveals that almost all
insulin is secreted in the pulsatile mode (18,22). However, in the present studies in vitro
examination of the insulin released by perifused human islets reveals a that the proportion
of insulin secreted in discrete bursts is -30-50% (or more). This apparent difference might
be due to the inefficiency of insulin delivery from the islet (3- cells in vitro into the
perifusion system compared with the delivery of insulin to the portal vein in vivo. In the
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latter context, (3-cells discharge insulin vesicles into capillaries, which have a relatively
high blood flow moving past all the P-cells prior to the collection of this blood into the
pancreatic veins and the portal vein. In contrast, in vitro, the capillaries in the islets are lost
and insulin secreted by P-cells (located predominately in the core of the islet) would be
delivered into spaces within the islet, from which it could diffuse to the biogel in which the
islet is embedded and then to the buffer to be delivered from the perifusion apparatus.
Insulin might transiently adhere to biogel beads and the walls of the collecting vessels prior
to appearing in the eluate. These factors would be expected to result in a damping of the
waveform of the insulin released by the islet, which would contribute to the predicted effect
of underestimating the proportion of insulin released in discrete bursts. Moreover, the
removal of the islets from the pancreatic neural network and other paracrine influences may
influence the secretory behavior of these cell clusters.
In summary, in the present study we have established the conditions for reliable detection
of pulsatile insulin secretion from human islets in an in vitro perifusion system. Application
of the system to human islets reveals that in general perifused islets behave remarkably
alike islets in vivo. Thus, we confirm that insulin is released in pulses at an interval of ~6-8
minutes and that regulation of insulin secretion (stimulation by increased potassium or
glucose concentrations) is achieved predominately by amplification of the magnitude of
these insulin bursts. The minimum proportion of insulin released by isolated islets that can
be confidently ascribed to discrete insulin bursts is lower that which we have previously
observed in vivo. This could reflect some degree of anatomic disruption of the islet and/or
decreased resolution of pulses per se. The present system should allow more detailed
examination of the factors that generate and regulate discrete insulin bursts by human islets.
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Diazoxide attenuates glucose-induced defects in first phase and pulsatile
insulin secretion in human pancreatic islets
Introduction
Diabetes mellitus is characterised by hyperglycaemia and impaired glucose mediated insulin
secretion (1). It has been shown that chronic hyperglycaemia per se leads to a reversible defect
in insulin secretion. One explanation for this is a decrease in p cell sensitivity to
hyperglycaemia (desensitisation) (2). Another explanation is that chronically increased demand
on insulin stores leads to a relative decrease in available insulin vesicles for secretion. Insulin
stores have been shown to be depleted in animal models of chronic hyperglycaemia (3), islet
cultures at high glucose (4) and in pancreatic extracts from patients with type 2 diabetes
mellitus (5). If depleted insulin stores contribute to decreased insulin secretion under conditions
of chronic hyperglycaemia then temporary inhibition of insulin secretion would be expected to
lead to at least partial restoration of these stores as well as insulin secretion.
In animal models of chronic hyperglycaemia inhibition of insulin secretion by diazoxide has
been shown to restore insulin stores and first phase and second phase insulin secretion (6).
In human studies one-week treatment with diazoxide in patients with type 2 diabetes
restored first phase insulin secretion (7) and overnight inhibition of insulin secretion with
somatostatin restored first phase insulin secretion and pulsatile insulin secretion (8).
In the present studies we examined insulin content and insulin secretion (in static
incubations and islet perifusions) to address the following hypotheses. First, we
hypothesised that prolonged (96 hour) incubation of islets at physiological increased
glucose concentration (11 mmol/1) leads to decreased islet insulin content and decreased
insulin secretion. Second, we hypothesise that inhibition of insulin secretion under these
conditions (diazoxide) leads to a relative preservation of islet insulin stores and secretion. If
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the latter hypothesis is confirmed the implication is that at least a component of defective
glucose mediated insulin secretion following prolonged exposure of islets to increased
glucose concentrations is attributable to depletion of insulin stores. Thirdly, that the
magnitude of insulin pulses secreted by an islet is related to the islet insulin stores. Finally,
that the increment in insulin secretion following prior diazoxide treatment is achieved
through amplification of the magnitude of insulin pulses.
Methods and materials
Overall experimental design
The purpose of the current studies was to determine the impact of transient inhibition of
insulin secretion on the subsequent pulsatile and first phase insulin secretion by human
islets. To accomplish this, batches of 5-20 islets were incubated for periods of 1 hr, 24 hrs
and 96 hrs in the presence or absence of 0.5 mmol/L diazoxide or 500 nmol/L somatostatin
prior to measurement of first and second phase insulin secretion. In order to measure
pulsatile insulin secretion and first phase insulin release islets were perifused at a
stimulating glucose concentration of 20 mmol/L perifusate collected at one minute intervals
for 40 minutes. Following islet perifusion the islets were salvaged to measure the total islet
insulin content. This provided the opportunity to examine the relationship between changes
in islet insulin content (achieved during the static incubations) and subsequent first phase
and pulsatile insulin secretion.
Islet isolation
Human islets were isolated from pancreases retrieved from 3 heart-beating organ donors by
the department of surgery at the University of Leicester. No donor had a history of diabetes
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mellitus. After isolation, islets were cultured in RPMI 1640 medium containing 5.5 mmol/1
glucose, 2 mmol/L glutamine, 10% fetal calf serum, 100 U/ml benzylpenicillin and 0.1
mg/ml streptomycin. Culture period in Leicester varied between 1-5 days before islets were
sent to Edinburgh. After arrival at this laboratory, islets were transferred to new RPMI 1640
medium (same composition as above) and cultured for at least 2 days before experiments
were performed. Time elapsed from islet isolation in Leicester to the start of actual
experiment was 9±2.2 days (range 3-13).
It was important to have islets of comparable insulin content at the start of each protocol
arm. We therefore sized islets (by microscopy) and distributed islets to each group for
subsequent study so that they included comparable proportions of small (80-160 pm)
intermediate (160-240 pm) and large (240-300 pm) islets.
Experimental protocol
(I) Static incubation (Table 1)
Islets were cultured at 37 °C with an atmosphere of 5% CC>2/95% O2. The islets were
incubated for 3 different time periods (1 hr, 24 hrs and 96 hrs) in 3 mis of RPMI 1640
culture medium. In the 1-hr and 24-hr incubation groups, batches of 20 islets were cultured
in 5.5 mmol/L and 11 mmol/L glucose in presence of 0.5mmol/L diazoxide, 500 nmol/L
somatostatin or control RPMI 1640 medium. In the 96-hr incubation group, batches of 5-10




Conditions of static incubation with corresponding duration of culture, glucose












1 5.5 V V V
1 11 V V V
24 5.5 V V V
24 11 V V V
96 11 V V
At the end of each incubation period, the culture medium was collected for analysis of
insulin concentration to allow calculation of insulin secretion during the static incubation.
The islets were transferred immediately to the perifusion protocol.
(2) Islet perifusion
After the static incubation period, islets were periperfused using a temperature-controlled
multichamber perifusion system (ACUSYST-S; Cellex Biosciences, Minneapolis, MN).
Islets were removed from the static incubation media, and immediately suspended in Bio-
Gel P-2 beads (Bio-Rad, Hercules, CA) and placed in aliquots of 5-20 islets 500 uL
perifusion chambers. The perifusion system consisted of a multi-channel peristaltic pump
which delivered perfusate through 6 parallel tubing sets via a heat exchanger and six
perifusion chambers. The peristaltic pump drew perifusate at a rate of 0.3 ml/min and
delivered it through the heat exchanger where it was warmed to 37 °C and gassed with 95%
O2. From the heat exchanger, the perifusate was delivered to the perifusion chambers
containing the human islets. The perifusion protocol consisted of exposing the islets to
Kreb's Ringer bicarbonate buffer perifusate (115 mmol/L NaCl, 4.7 mmol/L KC1, 2.5
mmol/L CaCl2, 1.2 mmol/L MgCl2, 5 mmol/L NaOH) supplemented with 0.2% human
serum albumin, 1 mol/L HEPES, 2 mmol/L glutamine, 100 U/ml benzylpenicillin, 0.1
mg/ml streptomycin and 20 mmol/1 glucose for 45 minutes. Effluent perifusate was
collected at 1-minute interval and stored at -20 °C and subsequently analysed for insulin
concentration.
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(3) Measurement of islet insulin content post-perifusion
At the end of perifusion period, islets were recovered from the perifusion chamber for the
measurement of its insulin content as previously described (9). The islets were washed in
RPMI 1640 and lysed with 600 pL ice-cold lysis buffer (50 mM Hepes, 0.1% (vol/vol)
Triton X-100, 1 pM PMSF, 10 pM E-64, 10 pM pepstatin A, 10 pM TLCK, 100 pM
leupeptin: pH 8.0). After sonication (25W for 40 s) and centrifugation (12000 g for 5 mins),
the resultant supernatants were stored at -20 °C and subsequently analysed for insulin
concentration and thus islet insulin content.
Assays
Glucose. Glucose concentrations were measured by glucose oxidation method using a
glucose analyser (Beckmann, Palo Alto, CA).
Insulin. Insulin concentrations were measured in duplicate by two-site immunospecific
insulin ELISA assay as previously described (10). The assay uses two monoclonal murine
antibodies (Novo Nordisk, Bagsvaerd, Denmark) specific for insulin. There is no cross-
reactivity with proinsulin and split 32,33 and 31,32 proinsulins. Sensitivity of the assay is 5
pmol/1 and the detection range is 5-2000 pmol/1. The intra-assay and inter-assay CVs ranged
from 2.0-2.3% and 3.7-4.5% respectively.
Proinsulin. Proinsulin concentrations were measured in duplicate by two-site ELISA assay
(11). The assay uses two monoclonal antibodies specific for proinsulin (Novo Nordisk,
Bagsvaerd, Denmark). The detection limit is 0.05-20 pmol/L. Interassay CVs were 4.7% at
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a median of 2.3 pmol/L, 6.7% at 5.1 pmol/L and 8.7% at 10 pmol/L. There is no cross
reactivity with human insulin and C-peptide.
Calculations and statistical analysis
All results are expressed as mean ± SEM. First phase insulin secretion was defined by the
mean secretion rate in the first 9 minutes after exposure to 20 mmol/1 glucose and the
second phase secretion was defined as the mean secretion rate between min 10 and min 45
of the perifusion experiment. The total insulin secretion during perifusion was calculated as
the sum of first and second phase secretion.
Islet insulin content at the end of the perifusion experiment was calculated by:
[Equation 1]: Islet insulin content postperifusion (fmol/islet) = insulin content in lysis
buffer (fmol)/number of islets.
Islet insulin content at the end of the static incubation (and just prior to the perifusion) was
calculated as follows.
[Equation 2]: Islet insulin content post static incubation (fmol/islet) = Islet insulin content
postperifusion (fmol/islet) + [insulin released during perifusion (frnol)/ number of islets].
Islet insulin content prior to static incubation was then calculated by:
[Equation 3]: Islet insulin content pre static incubation (fmol/islet) = Islet insulin content
post static incubation (fmol/islet) + [insulin released during static incubation (fmol)/ number
of islets].
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Pulsatile insulin secretion was quantified by both cluster analysis and deconvolution
methods using parameters specifically developed and validated for the present apparatus
with human islets and the current assay (12). Please refer to chapter 4 of this thesis for full
details.
Statistical comparison was made by use of either the unpaired Student's t test, analysis of
variance or regression analysis. A p value of p<0.05 was considered to be significant.
Results
Insulin secretion during static incubations.
There was no significant difference in islet size (by design) or islet insulin content prior to
inclusion of the islets in any of the protocols (Table 2). During static incubation of human
islets, insulin was released into the media under all conditions of study. As expected,
insulin release increased at 5.5 vs 11 mmol/1 glucose concentrations (7 hour; 13.8 ± 7.2 vs
40.4 ± 14.9 fmol/islet/hr, 24 hours; 2.6 ± 0.38 vs 20.7 ± 5 fmol/islet/hr, p<0.05). Islets
cultured at a glucose concentration of 11 mmol/1 for 96 hrs had a progressive but borderline
significant reduction in insulin release rate (e.g. control islets at 1 vs 24 vs 96 hrs, 40.4±14.9
vs 20.7±5 vs 7.3±1.6 fmol/islet/min p=0.07 ANOVA). As expected, at physiological
increased glucose concentrations both diazoxide and somatostatin inhibited insulin
secretion. Thus, when islets were cultured for 24 hours at 11 mmol/L glucose, inclusion of
either diazoxide or somatostatin in the medium led to a decreased rate of insulin release
(SMS vs CON, 3±0.6 vs 20.7±5 fmol/islet/hr, p<0.05 and DZ vs CON, 3.2±0.8 vs 20.7±5
fmol/islet/hr, p<0.05). Similarly, when diazoxide was added to culture medium over 96
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TABLE 2
Islet insulin content prior to static incubation. Islet insulin content is expressed in
the unit of fmol/islet. Results are expressed as the mean ± SEM of 4-6 experiments
SMS DZ CON
1 hr at 5.5 mM glucose 955.7±207.6 1016.2±205.6 735.61242.2
1 hr at 11 mM glucose 1013±262.4 1234.9±310.7 804.61255.5
24 hrs at 5.5 mM glucose 1571.4±437.6 929.61110.5 1231.11161.3
24 hrs at 11 mM glucose 1788.4±274.3 1559.81207.8 1947.81565.2
96 hrs at 11 mM glucose 1052.41261.8 919.71205.2
hours at a glucose concentration of 11 mmol/1, insulin secretion was decreased (figure la)
(DZ vs CON, 3.5±0.75 vs 7.3±1.6 fmol/islet/hr, p<0.05). In contrast, no effect of either
diazoxide or somatostatin applied for 1 hour was detectable on the mean insulin secretion
rate (at glucose 5.5 or 11.0 mmol/1) presumably reflecting the short period of study. Of
interest, when islets were incubated for 24 hours diazoxide and somatostatin inhibited
insulin secretion (p<0.05) at physiological high (11 mmol/1) but not basal (5 mmol/1)
glucose concentrations. In conclusion these data indicate that in the present studies the
islets responded appropriately by increasing insulin secretion in response to increased
glucose concentrations, and that this increased secretion rate was partially inhibited by
either somatostatin or diazoxide treatment at the physiological high glucose concentrations.
These conditions therefore allow us to test the posed hypotheses.
Islet insulin content after static incubation (Table 3)
Neither somatostatin nor diazoxide had any measurable impact on insulin content in islets
cultured for either 1 or 24 hours at 5.5 mmol/1 glucose. These observations were consistent
with the lack of a detectable impact of somatostatin or diazoxide on insulin secretion rates
by islets after they had been cultured under these conditions.
Islets cultured for 96 hours at 11 mmol/L glucose had a significantly reduced insulin content
compared to islets cultured at the same glucose concentration for 1 or 24 hours (control
islets, 1 vs 96 hrs, 762.5±250.8 vs 216.9±62.4 fmol/islet, p<0.05, 24 vs 96 hrs,
1451.7+462.6 vs 216.9+62.4 fmol/islet, p<0.05). This indicated that between 24 and 96
hours the rate of insulin release was greater than its rate of synthesis, thus, depleting islet




96-hr incubation at 11 mmol/L glucose. Insulin
secretion rate into culture medium was reduced
from pancreatic islets incubated in diazoxide.
This demonstrated the inhibitory effects of
diazoxide on glucose-induced insulin secretion.
TABLE 3
Islet insulin content after static incubation. Islet insulin content is expressed in
the unit of fmol/islet. Results are expressed as mean ± SEM of 4-6 experiments.
SMS DZ CON
1 hr at 5.5 mM glucose 955.71207.6 1016.21205 735.61242.4
1 hr at 11 mM glucose 987.11252.8 1200.51299.5 762.51250.8
24 hrs at 5.5 mM glucose 1561.9+441.1 913.81105.7 1197.81154.7
24 hrs at 11 mM glucose 1716.21263.6 1482.91198.6 1451.71462.6
96 hrs at 11 mM glucose 712.81190* 216.9162.4
* p<0.05 vs CON in 96 hr incubation at 11 mmol/L glucose
glucose led to a relative preservation of insulin content compared to control islets (figure
lb) (DZ vs CON, 712.8±190 vs 216.9±62.4 fmol/islet, p<0.05). This observation is
consistent with the observed decreased rate of insulin secretion by islets exposed to
diazoxide during the 96-hour studies.
First and secondphase insulin release duringperifusion
Islet insulin content predicted first or second phase insulin secretion. There was no
difference in the first or second phase insulin release as a result of prior incubation of islets
with diazoxide for 1 or 24 hours, neither of which was associated with a change in insulin
stores. However, incubation of islets at 11 mmol/L glucose with diazoxide for 96 hours
preserved islet insulin content relative to controls (see above) and also led to increased first
phase, (DZ vs CON, 6.0±0.97 vs 3.7+0.6 fmol/min/islet, p<0.05) and second phase insulin
secretion (DZ vs CON, 2.1+0.4 vs 1.2+0.2 fmol/min/islet, p<0.05) (figure lc, Id and
figure 2). There was a strong correlation between islet insulin stores at the start of the
perifusion and first phase (r=0.40, p<0.001) and second phase (r=0.60, p<0.001) during
perifusion (figure 3).
Pulsatile insulin release
Insulin pulses were detected in 66 of the 72 islet perfusions. The mean pulse interval was
8.9 ± 0.4 mins by cluster analysis and 6.6 ± 0.4 mins by deconvolution. The magnitude of
insulin pulses correlated with islet insulin content (r=0.5, p<0.001) whilst there was no such
correlation for inter-pulse interval (r=-0.06, p=0.6) (figure 4). Treatment with diazoxide had




96-hr incubation at 11 mmol/L glucose. At the end of the
static incubation period, the islet insulin content was
higher in pancreatic islets incubated in diazoxide. This




96-hr incubation at 11 mmol/L glucose. First phase






96-hr incubation at 11 mmol/L glucose. Second
phase insulin secretion is higher from pancreatic




96-hr incubation at 11 mmol/L glucose. Insulin
concentration profile during islet perifusion






Correlation between islet insulin content and first and second phase
secretion. There is positive correlation between islet insulin content















Islet Insulin Stores (fmol/islet)
Fig 4.
Correlation between islet insulin content and magnitude of
insulin pulses and inter-pulse interval. There is positive
correlation with the magnitude of insulin pulses but not
with inter-pulse interval.
mins, p=0.5 and cluster, DZ vs CON, 8.0 ± 1.5 vs 8.8 ± 1.4 mins, p=0.3). The increment in
the first and second phase insulin secretion observed in islets cultured at physiological
increased glucose concentration (11 mmol/L) with diazoxide were accompanied by an
increase in insulin secretion rate (deconvolution, DZ vs CON, 12.0 ± 2.3 vs 6.9 ± 1.1
fmol/min, p<0.05), pulse magnitude (deconvolution, DZ vs CON, 13.3 ± 1.6 vs 9.0 ±1.6
pmol/L, p<0.05) and islet insulin content at the start of perifusion (DZ vs CON, 712.8±190
vs 216.9±62.4 fmol/islet, p<0.05).
Islet insulin content a fter perifusion (Table 4)
Islet insulin content was higher in islets cultured with diazoxide for 96 hours at 11 mmol/L
glucose (DZ vs CON, 579.7±168 vs 138.8±60.8 fmol/islet, p<0.05). There was no
difference in islet insulin content following islet perifusion attributable to SMS or DZ at
either 1 or 24 hours incubations at 5.5 or 11 mmol/1 glucose.
Proinsulin/insulin ratio (96 hr incubation)
(1) Static incubation
The inhibitory effect of diazoxide on insulin secretion (DZ vs CON, 339.6 ± 72.2 vs 702.8 ±
154 fmol/islet/96hrs, p<0.05) was also reflected in the proinsulin release (DZ vs CON, 2.5 ±
0.7 vs 4.7 ± 1.2 fmol/islet/96hrs, p=0.06). Since the amount of insulin and proinsulin
secreted was reduced approximately 2-fold by diazoxide, there was no difference in the PI/I
ratio (DZ vs CON, 0.70 ±0.1% vs 0.67 ± 0.1%, p=0.4).
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TABLE 4
Islet insulin content after perifusion. Islet insulin content is expressed in the
unit of fmol/islet. Results are expressed as the mean ± SEM of 4-6 experiments.
SMS DZ CON
1 hr at 5.5 mM glucose 667.1± 186.9 837.9+177.5 529.6+138.4
1 hr at 11 mM glucose 686.1±130.2 891.7±265.8 392.3+229
24 hrs at 5.5 mM glucose 1297.2±397.2 681.9±142.1 976.5+153
24 hrs at 11 mM glucose 1398.4±209.2 1173.8+222.3 1103.6+399.4
96 hrs at 11 mM glucose 579.7± 168 * 138.8+60.8
*p<0.05 vs CON in 96hr incubation at 11 mM glucose
(2) Islet perifusion
During perifusion, there was no difference in the mean proinsulin concentration released
from islets treated with diazoxide (DZ vs CON, 0.16 ± 0.03 vs 0.20 ± 0.06 pmol/L, p=0.3).
In contrast, the mean insulin concentration secreted was higher from these islets (DZ vs
CON, 72.8 ± 12.8 vs 29.5 ± 3 pmol/L, p<0.01). Therefore, diazoxide significantly lowered
the perifusion PI/I ratio by approximately 71% (DZ vs CON, 0.2 ± 0.03% vs 0.7 ± 0.2%,
p<0.05) (figure 5a).
(3) Islet content post-perifusion
Following perifusion, the islet insulin content was reduced in the control islets (DZ vs CON,
579.7 ± 168 vs 138.8 ± 60.8 fmol/islet, p<0.05). In contrast, there was no significant
difference in the islet proinsulin content (DZ vs CON, 4.7 ± 1.2 vs 3.5 ± 1.4 fmol/islet,
p=0.2). Therefore, diazoxide significantly reduced the islet content PI/I ratio following
perifusion by approximately 65% (DZ vs CON, 0.85 ± 0.04% vs 2.4 ± 0.3%, p<0.001)
(figure 5b).
Discussion
In the present study we report that incubation of human islets at a glucose concentration
typically present in patients with Type 2 diabetes mellitus (11 mmol/1) for 96 hours results
in depletion of insulin stores. We confirm that this depletion is decreased when insulin
secretion is partially inhibited by concurrent incubation of the islets with diazoxide and this
treatment leads to enhanced insulin secretion (first phase, second phase and pulsatile) in
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Post-perifusion islet content PI/I ratio. Following 96-hr
incubation at 11 mmol/L glucose, diazoxide reduced the
PI/I ratio by 65%.
It has previously been reported that human islets cultured at supra-physiological glucose
concentrations have depleted insulin stores (4,13,14). This study demonstrates that
incubating non-diabetic human islets for 96 hrs at a physiological high glucose
concentration (11 mmol/L) leads to depletion of islet insulin stores and associated
impairment of both first and second phase insulin secretion. These data support the concept
that one of the mechanisms by which prolonged hyperglycaemia leads to P-cell dysfunction
is through the depletion of the available insulin stores. If this concept is valid then
enhancement of insulin stores in islets of patients with Type 2 diabetes would be expected
to result in improved insulin secretion. Hales et al (7) reported improvement in first phase
insulin secretion in a group of patients with Type 2 diabetes who were treated with
diazoxide for one week. Normalising plasma glucose concentrations by diet, insulin and
sulphonylurea treatments also led to improved endogenous insulin secretion (15). More
recently, it was shown that patients with Type 2 diabetes who had temporary overnight
inhibition of insulin secretion by somatostatin infusion restored their first phase insulin
secretion and pulsatile insulin release (8). In vitro studies have demonstrated that the
improvement in insulin secretion was associated with an increase in islet insulin content.
90% pancreatectomised rats treated with diazoxide had improved insulin release during
pancreatic perfusion and this was associated with higher pancreatic insulin content (6).
Human pancreatic islets cultured at 27 mmol/L glucose for 48 hours had impaired glucose-
induced insulin secretion and depleted islet insulin stores and both these defects were
partially restored with diazoxide (13). It appears that the imbalance between insulin release
and synthesis resulting in depletion of insulin stores in conditions of chronic
hyperglycaemia can lead to p-cell dysfunction and that by 'resting' the P-cell from chronic
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hyperstimulation can partly reverse this defect through the enhancement of the islet insulin
content.
The relative proportion of proinsulin level (PI/I ratio) is elevated in subjects with Type 2
diabetes (16,17). Here we report that the PI/I ratio observed during dynamic islet perifusion
and in the post-perifusion islet content are both decreased in islets cultured in diazoxide at
high physiological glucose concentration (11 mmol/L). The aetiology of elevated PI/I ratio
has been postulated to be the consequence of intrinsic (3-cell defect (in the processing of
proinsulin) (18,19) or the release of immature (proinsulin-rich) granules which are
accumulated in higher proportion than the mature (insulin-rich) granules within the islet
following hyperglycaemia-induced hyperstimulation of the (3-cell (20,21). The results of the
present study support the latter hypothesis. Diazoxide, which blocks glucose-induced
insulin secretion and opposes the effect of hyperstimulation, causes a higher proportion of
insulin to be accumulated within the islet whilst the absolute amount of proinsulin remains
unchanged. This results in the reduction of the relative proportion of intra-islet proinsulin
(PI/I ratio) observed here. This effect is also seen in the dynamic perifusion where a higher
proportion of insulin is released relative to proinsulin from islets incubated in diazoxide at
high physiological glucose concentration, presumably reflecting the mobilisation of these
mature insulin-rich granules.
Depletion of the pancreatic and islet insulin content has been shown to be associated with
defective glucose-induced insulin secretion (4,6,13,14). Further support for the role of
insulin content on insulin release was provided in an autopsy study which showed that
subjects with Type 2 diabetes have at least 50% reduction in their pancreatic insulin content
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(5). In the present study, we report a positive correlation between islet insulin content and
first phase and second phase insulin secretion. Pulsatile insulin secretion is also modulated
by islet insulin content. By employing the validated optimal criteria for pulse detection for
both cluster and deconvolution methods to analyse pulsatile insulin secretion from human
pancreatic islets (12), we report that the magnitude of insulin pulses is positively correlated
with the quantity of islet insulin stores whilst there is no such relationship for the inter-pulse
interval and that, the restoration of insulin secretion rate and magnitude of insulin pulses in
islets incubated in diazoxide were accompanied by increment in islet insulin stores. This
present study therefore yields further support for the role of islet insulin stores in the
modulation of the magnitude of insulin secretion and reaffirms that the regulation of
pulsatile insulin secretion is achieved through modulation of its pulsatile component at the
level of human pancreatic islets.
Is depleted insulin store as a consequence of P-cell hyperstimulation the sole explanation
for impaired insulin secretion observed in hyperglycaemic condition? The insight to this
question was provided by an observation made in this study. In islets cultured at
physiological high glucose concentration (11 mmol/L), the rate of insulin secretion into the
incubation medium declined from culture duration of 1 hour to 24 hours without any
significant change in the islet insulin content. Hence, depletion of islet insulin store per se
could not be the sole cause of impaired insulin secretion. High glucose condition or other
unknown factor(s) can impose deleterious effect on the machinery involved in glucose-
induced insulin secretion. Various hypotheses has been proposed such as defects in insulin
gene transcription (14,22), decreased insulin mRNA expression with associated proinsulin
biosynthesis (22,23), defective glucose metabolism (24), defective function of ATP
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sensitive K+ channel (25) and accumulation of glycogen within P-cell (26). Thus, it is
plausible that one or more of these factors could also contribute to P-cell dysfunction and
hence, restoring islet insulin content only remedies one of the factors causing defective
glucose-induced insulin secretion. This could explain the partial restoration of first phase
insulin secretion following a period of P-cell rest in patients with Type 2 diabetes (27,28).
More recently, it has been demonstrated that diazoxide only partially restore insulin content
in human islets cultured in high glucose conditions (27 mmol/L) (13).
Another interesting observation is that diazoxide confers beneficial effect on insulin
secretion only in condition which results in depletion of islet insulin stores. In islets cultured
at high physiological glucose concentration for 24 hours, pre-treatment with diazoxide and
somatostatin had no positive effect on first phase and second phase insulin secretion.
However, this is in contrast to the islets cultured at high physiological glucose concentration
for 96 hours which resulted in significant depletion of insulin stores and pre-treatment with
diazoxide in this group of islets led to improvement in insulin secretion. This observation is
in agreement with those of Leahy (6) and Grill (29) who noted in diabetic rat models the
need for reduced insulin content to see the full protective effect of diazoxide on insulin
secretion. Therefore, it is logical to conclude that the beneficial effect of P-cell rest on
insulin secretion only occurs in conditions that result in excessive insulin release
outstripping its synthesis capacity.
What are the implications of the protective effects conferred by diazoxide on insulin
secretion? Firstly, it strengthens the hypothesis that chronic p-cell stimulation can lead to
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defective insulin release and this could be partly explained by depletion in islet insulin
content. Secondly, it provides a potential method to treat type 2 diabetes therapeutically. For
example, the pancreas could be rested overnight during which time requirement for insulin
secretion is lowest allowing the pancreatic insulin stores to accumulate and to be released in
greater quantities in response to meal ingestion during daytime. Ideally, a pharmacological
agent without significant side effect(s) and with short half-life might be suitable. The short
half-life will allow shorter time for the drug to exert its effect and also for its inhibitory
action to disappear fairly rapidly to allow the release of insulin. Thirdly, P-cell rest
conferred by diazoxide has been shown to prevent the progression to diabetes in fatty
diabetic zucker rats (30). This has implication that not only that p-cell rest could be
beneficial in the treatment of established diabetes but also in reducing or preventing the risk
of progressing to clinically overt diabetes especially in high-risk individuals ie siblings of
diabetic patient, first-degree relatives or subjects with metabolic risk factors. Fourthly,
chronic administration of diazoxide has been shown to preserve endogenous insulin
secretion in newly diagnosed type 1 diabetic patients (31). This provides further support for
the beneficial effects of P-cell rest and also demonstrates that it is also effective in type 1
diabetes which has a different (autoimmune) aetiology from type 2 diabetes.
In summary, we have shown that culturing non-diabetic human islets for 96 hours at
physiological high glucose (11 mmol/L) typically observed in Type 2 diabetes subjects
leads to depletion of islet insulin stores and defective insulin secretion. Incubating these
islets with diazoxide improves the glucose-induced insulin secretion (first phase, second
phase and pulsatile) and this is associated with restoration of islet insulin stores. Islet insulin
stores correlates positively not only with first phase and second phase insulin secretion but
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also with the magnitude of insulin pulses. Finally, the regulation of pulsatile insulin
secretion from human islets is achieved predominantly through selective amplification of
the pulse magnitude whilst its frequency remains unchanged.
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Following the completion of these projects, a few interesting observations and conclusions
were made.
Pulsatile insulin secretion is regulated via selective amplification of the secretory burst
mass. It is secreted almost exclusively in discrete bursts in vivo. However, in perifused
islets, the proportion of insulin secreted in discrete bursts is less possibly as a consequence
of anatomical disruption of the islet and/or decreased pulse resolution.
The frequency of insulin pulses in human portal circulation is similar to those observed in
the portal circulation of dogs and in vitro isolated perfused islets. Moreover, it is also
comparable to those observed in systemic circulation in vivo when insulin concentration
was assayed by using highly sensitive immunoassay and analysed by validated
deconvolution method. This resolved the discrepancy in the literature regarding the
frequency of pulsatile insulin secretion in vivo. Furthermore, it implies that the activity of
the pancreatic pacemaker is remarkably consistent and stable in both in vivo and in vitro
conditions.
Another important observation is that the liver is exposed to large oscillations of insulin
concentration and the modulation of hepatic insulin clearance by the magnitude of insulin
pulses in portal vein. Physiological studies which examined the effects of pulsatile insulin
delivery on hepatic insulin action utilised oscillations of insulin concentration that were less
than those observed in the portal vein. This may have implications on the interpretation of
the physiological actions of pulsatile insulin delivery on the liver.
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The importance of distinguishing the oscillations in insulin concentration as a consequence
of model and assay noise from true pulsatile insulin secretion was highlighted in the
validation study. This is particularly important in the analysis and interpretation of the
oscillations in insulin concentration from isolated perifused islets where the absolute insulin
concentration levels can be low.
Chronic hyperglycaemia at levels observed in Type 2 diabetes can result in defective insulin
secretion and depleted islet insulin stores. 'Resting' the p cells (with diazoxide) can restore
the first and second phase and pulsatile insulin secretion. This was associated with increased
islet insulin content. The importance of islet insulin content on insulin secretion was
emphasised by the observation of the excellent correlation between islet insulin content and
the magnitude of insulin secretion (first and second phase and magnitude of insulin pulses).
This strengthens the hypothesis that impaired glucose-induced insulin secretion including
pulsatile secretion is at least partially due to depleted insulin stores as a consequence of
hyperglycaemia-induced chronic overstimulation of P-cells.
In conclusion, the dynamics of insulin secretion are important as well as the absolute
secretion and that the abnormalities in these dynamics may be partly related to (3-cell insulin
stores which can be manipulated by transient P-cell rest. Since the discovery that insulin is
secreted in pulsatile manner, its importance has been increasingly recognised in the
pathophysiology of diabetes mellitus. It is hoped that the results emanating from this MD
thesis might contribute in some way to the understanding of the physiology of insulin
secretion and the potential therapeutic application in clinical diabetes.
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